Introduction and Objectives: In a novel study design for medical devices, patients who received a blinded sham to mimic the Prostatic Urethral Lift (PUL) were unblinded after three months and then underwent PUL. As such, each patient acted as his own control in a comparative analysis. We present the 4-year durability data from this study. Methods: Fifty-three patients underwent sham procedure as part of the blinded, randomized L.I.F.T. study at 19 centers and elected to enroll in this crossover study. The crossover procedure involved placement of permanent UroLift â implants into the prostatic lateral lobes. Patients were followed for 3 months after sham and then 4 years after crossover PUL with assessments of urinary symptom relief, quality of life, urinary flow rate, sexual function, and adverse events. Results: At 4 years after crossover procedure, average IPSS, quality of life (QOL), and BPH Impact Index (BPHII) remained improved 45%, 49%, and 44% from baseline, respectively (p < 0.001). Mean peak flow rate (Qmax) increase of greater than 50% was also durable to 4 years (p = 0.01). Both IPSS and Qmax improved within 2 weeks of sham. IPSS returned to near baseline after 3 months of sham, while flow remained slightly elevated (Figure 1) . After crossover PUL, both symptoms and flow improved to a greater extent than after sham, and remained durable to 4 years. There were no reported instances of de novo, sustained erectile or ejaculatory dysfunction. Patients returned to normal activity within 7 days of crossover PUL. Adverse events associated with the procedure were typically mild to moderate and resolved within 2 weeks.
Introduction and Objectives: In a novel study design for medical devices, patients who received a blinded sham to mimic the Prostatic Urethral Lift (PUL) were unblinded after three months and then underwent PUL. As such, each patient acted as his own control in a comparative analysis. We present the 4-year durability data from this study. Methods: Fifty-three patients underwent sham procedure as part of the blinded, randomized L.I.F.T. study at 19 centers and elected to enroll in this crossover study. The crossover procedure involved placement of permanent UroLift â implants into the prostatic lateral lobes. Patients were followed for 3 months after sham and then 4 years after crossover PUL with assessments of urinary symptom relief, quality of life, urinary flow rate, sexual function, and adverse events. Results: At 4 years after crossover procedure, average IPSS, quality of life (QOL), and BPH Impact Index (BPHII) remained improved 45%, 49%, and 44% from baseline, respectively (p < 0.001). Mean peak flow rate (Qmax) increase of greater than 50% was also durable to 4 years (p = 0.01). Both IPSS and Qmax improved within 2 weeks of sham. IPSS returned to near baseline after 3 months of sham, while flow remained slightly elevated (Figure 1) . After crossover PUL, both symptoms and flow improved to a greater extent than after sham, and remained durable to 4 years. There were no reported instances of de novo, sustained erectile or ejaculatory dysfunction. Patients returned to normal activity within 7 days of crossover PUL. Adverse events associated with the procedure were typically mild to moderate and resolved within 2 weeks.
Conclusions:
The Prostatic Urethral Lift procedure offers patients rapid and durable relief in symptoms, increased urinary flow rate and improved quality of life. Morbidity has been shown to be low and sexual function is preserved. The crossover study design produced results similar to those obtained in randomized comparison.
Introduction and Objectives: New treatment options are being developed for men with benign prostatic enlargement who fail medical therapy and are unsuitable for surgery. One such treatment that is gaining popularity is prostatic artery embolization. This study aims to assess the safety and feasibility of prostate artery embolisation as a treatment for lower urinary tract symptoms (LUTS) caused by prostate enlargement. Secondary outcome measures will assess the effectiveness of prostate artery embolization. Methods: Male patients with benign prostate enlargement and LUTS, who had failed medical therapy and were unsuitable for, or declined, surgical intervention were recruited to undergo prostate artery embolisation. Patients with a prostate size >40 cc, with severe symptoms as rated on the international prostate severity score (IPSS), who had obstructive urodynamics with Qmax of <12 ml/s, or were in acute urinary retention, were deemed suitable to undergo a PAE. All patients either declined or were deemed unsuitable for surgical intervention. Ethics approval was received from the Uniting Healthcare Human Research and Ethics committee. MRI prostate, CTA pelvic arteries and urinary Q-max assessments were performed prior to catheter directed angiograms of prostatic arteries, via either a right common femoral or left brachial artery approach. Flat-panel dyna-CT was used to confirm correct catheter position and prevent off-target embolisation. Dilute 250 micron embozene particles were used to occlude the prostate arteries to stasis. Patients were followed-up at 1, 2, 4 weeks and 3 months post-embolisation. Results: Thirty-five patients underwent PAE; 26 patients had LUTS, 2 patients had intractable haematuria and LUTS, and 7 patients had catheter dependent retention. No major complications or significant peri-procedural adverse events were recorded. Technical success, namely embolisation of at least one prostate artery, was achieved in all patients. IPSS and QoL scores improved significantly in over 91% of patients. Improvements in maximum urinary flow, reduction in postvoid residual bladder volumes and decreased prostate volumes were also observed at 3-month follow-up. Conclusions: PAE is a safe and feasible treatment for symptomatic benign prostate enlargement. Early data indicate PAE can significantly reduce symptoms and improve quality of life, decrease prostate size, improve urinary flow and reduce post-void residual urine volumes. Recruitment and data collection for inclusion in a comprehensive PAE registry is ongoing, to further determine the clinical role of PAE.
Introduction and Objectives: Asymptomatic, elevated post-void residual urine volume (PVR) is often found incidentally in older men although the prevalence in the general population has not been studied. The aim of this study was to describe the natural history of PVR in communitydwelling older men. Methods: The Concord Health and Ageing in Men Project involves a representative sample of community-dwelling men aged 70 and older in a defined geographic area of Sydney, Australia. The participants underwent uroflowmetry and PVR measurement at baseline and two-year and five-year follow-up. PVR was considered valid when the voided volume was 150 mL and over. Men who had neurological diseases or prostate cancer at any follow-up point and men who had a history of urological treatment at baseline were excluded from the analyses. Results: 329 men who had valid baseline PVR data and were followed up for five years were included in the analyses. 15 of 325 (5%) men with a baseline PVR of less than 400 mL and 3 of 4 men (75%) with a PVR of 400 mL and over had surgery for benign prostate enlargement (BPE) or indwelling catheterization over five years. In all 101 men with a baseline PVR of less than 400 mL who did not receive urological treatment during follow-up and had valid PVR data for both two and five-year follow-up, PVR did not exceed 400 mL at either follow-up time point. Baseline PVR did not predict hospitalisation for retention or UTI. Conclusions: Conservative management may be appropriate for most older men with incidentally found elevated PVR of less than 400 mL.
Fibrinogen concentrate effect on perioperative bleeding in transurethral resection of the prostate: a double blind placebocontrolled and randomized study Introduction and Objectives: Hemorrhage during transurethral resection of the prostate (TUR-P) has always been a concern. Several studies have shown promising results of pre-operative administration of fibrinogen concentrate in reducing hemorrhage in cardiac surgery. This study investigated the hemostatic effect of fibrinogen concentrate administration on reducing the bleeding amount during TUR-P in patients with benign prostatic hyperplasia. Methods: Sixty men with benign prostatic hyperplasia, who were candidate to undergo TUR-P, entered this prospective randomized double-blind placebo-controlled pilot study. The participants were randomly assigned into two groups: treatment (n = 31) and placebo (n = 29).They received an infusion of 2 gr fibrinogen concentrate (treatment group) or normal saline (placebo group) before surgery. The bleeding amount, operation data and complications were recorded and analyzed. Results: Both groups were statistically similar regarding demographic and clinical characteristics. No significant decrease in bleeding was observed during (521 ml vs. 557 ml, p = 0.9) and after (291 mLvs. 341 ml, p = 0.8) surgery between the two groups. This lack of difference was also seen in operation time (43 vs. 42 min, p = 0.86), irrigating fluid volume used during (17 vs. 19 liters, p = 0.43) and after operation (29 vs. 28 liters, p = 0.8), and resected adenoma volume (19 vs. 19 gr, p = 0.92). As a confounding factor in the bleeding amount, mean blood pressure was also similar in both groups. Conclusions: Preoperative administration of fibrinogen concentrate had no significant influence on intra-and post-operative bleeding during TUR-P. Introduction and Objectives: The Prostatic Urethral Lift (PUL) has been shown to offer rapid improvement in LUTS with low morbidity, less frequent need for post-operative catheterization and a unique preservation of sexual function. We present the 5-year results concluding the largest multi-center, randomised, blinded trial of the Prostatic Urethral Lift. Methods: At 19 centers across Australia and North America, 206 men with symptomatic LUTS secondary to BPH were randomised to PUL (N = 140) or sham control (N = 66). Enrollment criteria included age≥50 years, IPSS≥13, Qmax≤12 ml/s, and prostate volume ≤80 cc. PUL entails transurethral, endoscopically guided placement of small permanent metallic implants into the lateral lobes of the prostate, holding the lobes in a retracted position, opening the prostatic urethra, and thus reducing urinary obstruction. Through 3 months, patients and assessors were kept blinded to treatment arm. Assessments for the PUL participants continued through 5 years and included IPSS, quality of life on the IPSS form (QOL), BPH Impact Index (BPH II), Qmax, Sexual Health Inventory for Men (SHIM), and Male Sexual Health Questionnaire for Ejaculatory Dysfunction (MSHQ-EjD).
Results: IPSS and QOL improved 44% and 42% by 1 month and remained improved by 38% and 54%, respectively, through 5 years (p < 0.001). Qmax remained improved 41% at 5 years. Adverse events were typically mild and transient, most frequently hematuria, dysuria, pelvic pain, urgency and urge incontinence. There was no occurrence of de novo, sustained erectile or ejaculatory dysfunction. Sexual function assessments (SHIM, MSHQ-EjD) show stable erectile function average score and improved ejaculatory function and ejaculatory bother average scores (p < 0.001).
The Prostatic Urethral Lift offers a low morbidity treatment that offers rapid improvement and preservation of sexual function for men suffering from BPH. Now with these concluding results to the largest randomized multi-center study, PUL has demonstrated acceptable durability to 5 years.
Endo-urology/Stones
The age of ureteroscopy: where did all the stones come from?
Introduction and Objectives: The incidence of urolithiasis is increasing in the Western population. Significant advances in ureteroscopy and stone fragmentation energy sources has resulted in a paradigm shift in urolithiasis management. We aimed to assess the current state of urolithiasis management in Australia over the last 15 years using population-based data.
Methods: Medicare Australia databases were accessed and Medicare rebate codes pertaining to ureteroscopy, extra-corporeal shockwave lithotripsy (ESWL) and percutaneous nephrolithotomy (PCNL) were extracted per state, year and gender between 2001 and 2015. Population data was extracted from the Australian Bureau of Statistics website and provided the "population at risk" denominator to calculate incidence proportions. Introduction and Objectives: Ureteric calculus size and passage rates have been investigated in the past. However, there was a gap of knowledge on which measurement of stone size should be used. Whether it should be the maximum diameter of the calculus in any plane or just the axial plane, remains to be answered. Radiological reporting is also not standardised to one dimension either. This retrospective observational audit aims to address that question. Methods: Non-contrast renal tract CT scans for all patients who presented to our hospital with renal colic between 01/01/ 2016 and 30/06/2016 were analysed. Maximal axial (MA), perpendicular axial (PA) and maximal coronal (MC) diameters of each ureteric calculus were measured. Each patient was followed-up for the next three months to record the outcome of each calculus. The main interest of this study, ovalshaped/elongated calculi which were passed spontaneously, were few. Of these, only 14, 5 and 3 calculi had differences of at least 1.0, 1.5 and 2.0 mm between the MA and MC diameters. The Pearson correlation coefficient (R) between days taken to pass the calculus and MA, PA and MC diameters were À0.089, À0.118, and À0.091 (all p > 0.05).
Conclusions: Ureteric calculi which passed spontaneously tend to measure ≤5 mm in all three dimensions whereas this was less likely in calculi requiring surgery. Weak negative correlation was found between the time it took for oval-shaped/ elongated ureteric calculus to pass and individual dimensions of the calculus. A larger sample size is required to more accurately determine which of the three dimensions of a ureteric calculus affects the rate of stone passage. If answered, it may help to more accurately predict ureteric calculus that will pass spontaneously and those that will require surgery. This report is exported into a Microsoft Excel spreadsheet that auto-populates the patient's MRN, name, and the date of the procedure. The department secretary cross matches these details to the patient's electronic operation report in order to determine the intended date of stent removal. As this date passes the register generates automatic prompts to check the patient's electronic medical records to determine if the stent was removed as planned. Prospectively, patients were identified who were at an elevated risk of being lost to follow-up based on the systems in place prior to the implementation of the stent register.
Results: Between 1 January 2016 and 30 June 2016, 457 stents were inserted in patients across the LHD. At the time of writing (3 months after the last stent considered in this study was inserted), 96.9% had either been removed or changed, or were due to be removed or changed as planned, with 14 stents which have yet to be removed or changed (3.1%, 95% Confidence Interval 1.6-4.7%).
A total of 22 stents were identified as having been at risk of loss to follow-up (4.8%, 95% Confidence Interval 2.8-6.8%). Conclusions: The semi-automatic electronic stent register represents an effective means of tracking and managing ureteric stents within a busy unit. Given the widespread introduction of electronic medical record and billing systems within Australia we submit that this style of register should represent the new standard of care.
Does bowel preparation or fasting improve stone visualisation and clearance in those undergoing SWL for intra-renal calculi?
Introduction and Objectives: Casey Hospital, Monash Health, is one of two centres in Victoria where Extracorporeal Shock Wave Lithotripsy (SWL) is performed using X Ray for stone visualisation. Currently patients fast for 2 h prior to the procedure. On the day of procedure, bowel gas can obscure visualisation of the calculus resulting in 8% of cases being cancelled. This study aims to review whether bowel preparation or fasting for 6 h prior to SWL will improve stone visualisation on the day of treatment, reduce cancellations and improve calculi clearance rates. Methods: This is a single centre, randomised controlled trial, with ethics approval granted from Monash Health Human Research and Ethics Committee (approval number: 16324A). Patients who were selected for SWL were then consented for participation in the trial. Patients were randomly allocated to one of the three arms of the trial; 1. Two sachets of Picoprep â were taken within 12 h of the procedure, 2. Six hours of fasting prior to the procedure or 3. Fasting for 2 h prior to SWL. Picoprep â sachets were provided by Fresenius-Kabi. Patients were included into the study if they had intrarenal calculi measuring between 8-12 mm. Patients were excluded from the study, if they were over 75 years of age, had more than three medical co-morbidities or had any cardiac/renal conditions. At six weeks post SWL, all patients had a CT KUB to assess stone clearance and were asked to complete a survey on their subjective experience of the trial. Statistical analysis was performed using SPSS, t-test. Results: Thirty patients were recruited in total, ten into each of the three arms. In the bowel preparation group, there were no cancellations on the day of SWL treatment. All stones were fragmented, with one patient needing a repeat treatment for a 5 mm intra-renal fragment. Of the patients who were fasting for either the 6 h or the 2 h, each group had one cancellation on the day of the procedure for poor visualisation of the calculus. This was a statistically significant difference of p = 0.03 between the bowel preparation and fasting groups. There was no loss to follow-up. Patient satisfaction was high across all three groups, including those who received bowel preparation. Conclusions: Giving bowel preparation within 12 h of SWL appears to be an effective method of reducing bowel gas interference and improving the calculi visualisation at the time of SWL, resulting in fewer cancellations. Fasting for extended periods of time does not seem to make a significant difference. We are in the process of recruiting more patients to the study.
Introduction and Objectives: Percutaneous nephrolithotomy (PCNL) is the standard treatment for large renal calculi. We compared the efficiency and complications of three models of intracorporeal lithotrites in treating stones >2 cm during PCNL. Methods: 270 patients were enrolled across nine participating sites in North America from 2009 to 2016. Patients were randomized to one of three lithotripter devices: Cyberwand, a dual probe ultrasonic device; Lithoclast Select combining the pneumatic and ultrasonic modalities; and StoneBreaker, a portable pneumatic device powered by CO 2 cartridges. StoneBreaker was used in combination with ultrasonic LUS-2 lithotriptor to allow fragment removal. Power calculations required 70 subjects in each of the three study groups. Primary study outcome was stone clearance rate (mm 2 /min). Stone surface area was measured in mm 2 on preoperative CT or KUB by the lead investigator. Results: 270 patients were enrolled, 69 were excluded after randomization. The most common exclusion reasons were: device not used (25%), data not available (23%), difficulties obtaining consent (17%) and inability to access the stone (14%). 201 patients completed the study, 71 in the Cyberwand group, 66 in the Lithoclast Select and 64 in the StoneBreaker. The results are presented in Table 1 . The three study groups were well matched on baseline characteristics. The stone surface area was slightly smaller in the Stone Breaker group. The stone clearance rate was slowest in the StoneBreaker group (24 mm 2 / min vs. 32 and 29 respectively). When the smaller average stone size in the StoneBreaker group was adjusted for, there was no difference in the stone clearance rate across the three groups (p = 0.249). Secondary outcomes, including complications and stone free rate were similar between We thus sought to compare outcomes of super-obese (BMI>50) patients undergoing PCNL versus both an "ideal BMI" and "typical BMI" cohort in a large, contemporary dataset. Methods: We used a prospectively maintained database to identify ideal , typical , and super-obese (BMI > 50) patients who underwent PCNL at our institution. Groups were compared across a range of characteristics. Our primary objective was to compare surgical outcomes between groups as measured by the percent of patients who required secondary PCNL. At our institution, patients with residual fragments on computed tomography performed the day following surgery almost uniformly undergo a secondary procedure, making this a surrogate measure of stone free rate. We compared complication rates, need for transfusion, and length of stay (LOS). Comparisons were made using chi-square testing and ANOVA where appropriate.
Results: A total of 1,152 patients were identified of which 254 were classified as ideal BMI, 840 as typical, and 58 as super obese. The typical cohort had a higher mean age and greater proportion of males, whereas staghorn stones were more common in the super-obese group. Otherwise, the groups were similar ( Introduction and Objectives: Incontinence is a complex disorder. This complicates the search for effective treatments, though pelvic floor muscle exercises (PFME) form the mainstay of treatment. It has a negative effect on women's quality of life and is a source of social embarrassment. PeriCoach TM system (PC) comprises a novel sensor device, web portal and smartphone app. The aim of this study was to evaluate the efficacy of the PC in females with stress, or mixed (predominantly stress) urinary incontinence and the degree of satisfaction with its use. Methods: 100 women aged ≥18 years who met inclusion criteria were screened before randomization to PFME/PC or standard PFME. All women were trained in PFME and received treatment for 20 weeks. The primary endpoint was ≥30% reduction in leakage in 24 h pad weight test at weeks 4 and 20. Other endpoints included Incontinence Quality of Life (IQOL), Prolapse/ Incontinence Sexual Questionnaire IUGA Revised (PISQ-IR), and PFM strength change. Change from baseline was compared using a Mixed ANOVA with group (PFME vs. PFME/PC), week (4, 20) and their interaction effects in the model. N (%) of subjects with 1-point increase in PFM strength was compared. Results: To date, 51 women have been randomized and available data analyzed. For IQOL, subjects in PFME/PC were more satisfied than the PFME group (p = 0.0037). Subscales of IQOL were all in favourable direction for PFME/PC with Psychosocial Impact highly significant (p = 0.0165) and Social Embarrassment borderline (p = 0.0520). Pad Weight data shows improvement in favor of PFME/PC group, lacking power for significant difference. The PISQ-IR presents statistically significant satisfaction in favour of PFME/ PC (p = 0.0003). Strength change of ≥1 point on Modified Oxford Scale is statistically significant for both groups (p < 0.0001) though no different between groups.
Other
Roles of urodynamics in the assessment of post radical prostatectomy incontinence: do findings change patient management?
Introduction and Objectives: Urinary incontinence post radical prostatectomy is aetiologically diverse, and not solely confined to post-surgical stress urinary incontinence (SUI). Previous studies have shown overall incidence of detrusor overactivity (DO) Introduction and Objectives: Smoking is an established risk factor for a number of common benign and malignant urological conditions. Public awareness of smoking as a risk factor for urological disease is thought to be poor, particularly when compared to other smoking-induced malignancies such as lung cancer. Our study aims to quantify the smoking status of Australian urology patients and evaluate their awareness of the health risks of smoking. Methods: A 34-question survey was given to consecutive urology patients in a public outpatient clinic. The questionnaire assessed patients' awareness of smoking as a risk factor for a range of urological conditions and other smoking-related diseases. Smoking habits and the perceived role for urologists in smoking cessation were also evaluated. Results: The 238 patients who completed the survey had a median age of 62 years (range 17-93 years) and 168 (80%) were male. The vast majority (92.3%) spoke English as their first language. 37 (17.6%) identified as current smokers, 79 (37.6%) were ex-smokers and 92 (44.8%) had never smoked. Patient awareness of smoking as a risk factor for various smokingrelated diseases are shown in Table 1 . Awareness of smoking as a cause of nonurological conditions (73.2%) was significantly higher than for urological diseases (37.3%). Smoking-related diseases featured in cigarette packet warnings had a higher rate of awareness than those that do not feature in such warnings (73.1% versus 43.6%). Only 11% of patients stated their urologist had discussed the risks of smoking while 28.1% felt their urologist should discuss their smoking. Among smokers, 40.5% of patients felt their urologist was in a good position to help them quit and 67.6% would be more likely to quit if suggested by their urologist. A majority of smokers (64.9%) would be more likely to quit if they thought it could help their urological condition. Conclusions: Australian patients have poor awareness of the effect of smoking on urological conditions, despite a wellestablished causal relationship in many diseases. There is potential for urologists to play an increased role in smoking education and cessation. Introduction and Objectives: A Urological telehealth service has been operating in Western Victoria since 2013, a catchment of 400,000 patients over 30,000 km 2 . This study investigated the perceptions of patients of accepting and using this service. Methods: All 229 patients that engaged with a urological telehealth service since its inception for a 2 year period were surveyed with a questionnaire comprising 39 questions of mixed construction, predominantly closed-ended Likert style statements. 153 of 210 surviving participants returned responses (73%) which were collated, de-identified, and analysed using appropriate statistical techniques. mean (SD 0.7, 4 questions); Follow-Up Satisfaction 3.9 mean (SD 0.7, 2 questions); and Financial Benefit 4.1 mean (SD 0.8, 2 questions). Further free text and numerical based questions elucidated: 97 patients (63.5%) preferred telehealth consultations over face-to-face, with 33 of those willing to change their response if a telehealth fee was introduced, 65 would change if face-to-face consultations were only conducted at more distant sites, and 25 participants stated that increasing complexity of disease was the main issue for a change of preference away from a telehealth service. Patients who lived further from the hospital preferred telehealth; the difference in patient's responses became significant at p = 0.05 level when distance exceeded 232.5 KM (78% of responders preferred telehealth, p-value 0.025). Conclusions: Overall patients' perceptions indicate they are satisfied and accepting of the urological telehealth service provided; with cost, distance and complexity being the main determinants. Introduction and Objectives: The timely and accurate follow up of intra-operative specimens remains a challenge in surgical departments especially in public healthcare where staff turnover is high. Missed or delayed follow up risks significant morbidity and even mortality. Here we describe the set-up of a robust system, the "urology histology clinic" (UHC), to follow up pathological specimens collected in a busy urology department. Methods: A weekly consultant only clinic with a cap of 10 (AE2) patients was set up where all patients who had surgical specimens collected were followed up within a two week period of their procedure. The consultant conducting the clinic rotated weekly and patients were reviewed by the consultant of the week irrespective of who the primary surgeon was. To generate referrals to the UHC an application 'e-blue slips' was created and compulsorily filled out by surgeons every time a specimen was collected. To co-ordinate both the clinic and referrals as well as to cross check all specimens, a dedicated clinical nurse coordinator (CNC) with significant urological experience was allocated 24 h per week to UHC program. His job included but was not limited to scheduling UHC appointments from referrals, cross checking theatre data to ensure all patients received referrals and ensuring pathology results were finalized prior to appointments. Results: Over twelve months, 667 patient specimens were referred to the UHC. The majority of specimens were prostate biopsies followed by bladder biopsies. Of all specimens collected intra-operatively only 9.2% of specimens were not referred to the UHC by the collecting surgeon. There were two distinct spikes of missed referrals in September and November. These periods correlated directly with a change in regular staff in the department. After the above process was undertaken and missed referrals were booked into the UHC, we had no patients with specimens collected requiring follow up who were not booked into the UHC.
Conclusions:
We have demonstrated the set up of a novel follow up system which has eliminated missed follow up of surgical specimens. Additionally, our UHC program allows easy audit of department activity and follow up of surgical patients.
A few drawbacks such as extra appointments and surgeons following up patients they did not operate on were noted however, due to the effectiveness of this system it remains in place in our department. We anticipate that with minor changes this system that can be widely adopted to improve patient outcomes.
Portable video media for urological education of junior medical officers and medical students: a prospective, randomised controlled, cross-over trial Introduction and Objectives: Continuing education of doctors is important for quality delivery of healthcare and surgical education opportunities for junior doctors at regional, rural and remote sites are limited. Traditional educational methods (e.g. conferences and tutorials) have many drawbacks for delivery of this type of information in a universal, standardised and timely manner and are nearly impossible in deliver in regional/remote Australia in a cost effective manner. The rapid uptake of portable media devices makes portable video media a potential alternative to current educational methods. Use of video media has been well studied in higher education and for education of patients; however there is a paucity of research for its use for continuing education of junior doctors, particularly in a regional/rural setting. Methods: Design: Prospective, multi-centre, randomised controlled crossover trial over a 1 year period between March 2015 to March 2016. Setting: Three regional/rural hospitals: Gosford District Hospital, Wyong Hospital and Lismore Base Hospital. 49 participants (37 intern doctors and 12 final year medical students).
Intervention: Surgical information regarding renal calculi and cystoscopy and ureteric stenting was delivered via portable video media (PVM), a 7 min video, compared to information delivered via standard verbal communication (SVC).
Outcome measures: Knowledge acquisition was measured by a 32-point questionnaire and satisfaction with the method of education delivery was measured using the validated Client Satisfaction Questionnaire (CSQ-8, max score 32). Participants completed these questionnaires following first intervention and crossover to the alternate intervention. The knowledge test was also administered prior to first intervention to gauge the participant's baseline knowledge.
Results: Within group analysis showed that both groups had significant increase in knowledge after first intervention, with the PVM group having a 25% increase in knowledge scores (20.18 vs. 25.14, 0.001) while the SVC group had a 16% increase in knowledge (22.67 vs. 26.26, p < 0.001). PVM was significantly more preferred than SVC with a higher CSQ-8 score (27.96 vs. 25.48, p = 0.007). Crossover analysis revealed that participants had a significant 11% increase in satisfaction with the education process when they crossed over from SVC to PVM (25.48 vs. 28.33, p < 0.001). Subgroup analysis of interns and medical students revealed the same statistical trends. Conclusions: This study is the first to demonstrate the benefits of using PVM for education of interns in a regional/rural location. Portable video media provides a novel method for providing education to interns and medical students. Our study shows portable video media improves knowledge retention and satisfaction with the educational process compared to traditional educational methods. Introduction and Objectives: Trauma is the sixth leading cause of death worldwide and the urological system is involved in 5-10% of patients presenting with moderate to severe trauma. This study aimed to detail the Urological Trauma Experience in our Major Trauma centre and report on the patterns of injuries, management and outcomes. Figure 1 shows the number of times where clinicians failed to make a referral to the UHC at the time of the operation for each month.
Methods: Institutional Review Board approval for this project was authorised (project RESP/16/201) by the NSW Health Northern Sydney Local Health District Research Committee. A retrospective analysis was performed on the prospectively collected Royal North Shore Hospital Trauma Service Database which is maintained by an accredited trauma registry manager according to the NSW Health Trauma minimum data set. The NSW Health Trauma minimum data set inclusion criteria are: 1. Admission to a trauma service in NSW within 14 days of injury, 2. Injuries classified as moderate to critical (i.e. an Injury Severity Score > 12) or 3. ICU admission or death in hospital. Patients suffering from Urological system injuries following moderate to severe trauma were analysed. Analysis was performed using SPSS 23.0. Results: Over a 4 year period (Jan 2010-Dec 2014) there were 2687 moderate to severe trauma admissions to our Major Trauma Centre. Urological injuries were recorded in 102 patients (4%) who had a combined 121 Urological injuries. The mean age of patients was 44.4 years and 79% were males. Blunt force injuries comprised 95.1% of all injuries. Renal injuries were the most common (57%), followed by adrenal (17.3%), bladder (15.7%), Urethral (3%), scrotal (2.4%), testis (2.4%) and penile (1.7%). 69% of cases presented to the Emergency Department out of normal working hours and 35% presented on the weekend. 29% of patients required transfer immediately to the operating theatres. 75% of cases had >8 day admissions and 80% were admitted to the intensive care unit with a median stay of 3 days during their hospital stay. 43% of patients were discharged to their home, 47% of patients required transfer to a rehabilitation facility and 10% of patients died during hospital admission. Conclusions: Our study is one of the first studies of urological trauma in Australia. Blunt trauma accounts for the most urological injuries with renal trauma being the most common injury. A significant amount of urological trauma presentations occur out of working hours and this has significant implications for workforce planning. Our results are similar to those published in the current international literature.
Is it feasible to discuss all urological cancer patients at the tertiary centre multi-disciplinary team meeting (MDT)? Introduction and Objectives: Multidisciplinary team meetings (MDTs) for diagnosing and treating patients with cancer are supported by evidence and recommended by guidelines.The use of an MDT may be particularly suited to Western Australian patients due to the vast land area that the population covers (2.5 million km 2 ), with 14% of the population living in rural or remote areas. The opening of a new public tertiary teaching hospital (PTTH) in Western Australia provided the opportunity to redesign the MDT with the aim of discussing all new urological cancers at least once. The meeting is inclusive of patients treated at a neighbouring level 2 hospital. The MDT design further allows for discussion of benign complex radiology cases towards the end of the meeting. Methods: Prospective data concerning all urology MDTs were collected over a 12 month period. Data was collated using the MDT electronic database (SHaRE). Attendance, number of cases discussed, patient demographics, case load and mix are reported. Results: There were forty seven MDT meetings during which one thousand and thirty discussions were conducted for a total of six hundred and forty six patients. Meetings were consistently well attended with an average of 4.4 consultant urologists, 2.1 urology registrars, 2.5 radiologists, 2.6 cancer nurses, 1.0 pathologist, 1.6 radiation and 1.7 medical oncologist. Cancer diagnoses accounted for 82.8% of cases discussed, with the remainder (17.2%) being complex benign cases. One hundred and fifty five patients were rural or remote and four hundred and ninety one were from the metropolitan area. Of all cancer cases discussed 41.3% were prostate, 25.1% Bladder, 24.5% renal, 5.4% Testis, and 1.7% penile (non-urological cancers made up 2.1%). An average 73.5% of cases discussed were from the host centre. The remainder referred from a neighbouring secondary hospital. 58.7% of cases discussed at each meeting were new and each patient was presented at an average of 1.6 MDTs.
Conclusions: A thorough MDT discussion of all new cancers presenting to a large PTTH is feasible. An efficient MDT process may be of particular benefit to rural/ remote patients as well as facilitating transfer of complex cases from secondary to tertiary hospitals.
Hybrid ⁶⁸Ga-PSMA PET-CT for primary prostate cancer staging J. LEE Royal Brisbane Hospital, Brisbane, Australia Introduction and Objectives: There are various limitations to conventional imaging techniques used in the staging of prostate cancer. Computed Tomography (CT) and whole-body bone scans are sensitive in detecting metastatic spread in advanced disease but lacks accuracy for loco-regional lymph node involvement. Magnetic Resonance Imaging (MRI) on the other hand may provide valuable information on nodal metastasis but is less useful than CT and bone scan in detecting distal disease. Often a combination of these imaging modalities is required for accurate clinical assessment to help determine the most appropriate therapeutic option. Hybrid Positron Emission Tomography with Computed Tomography using Gallium labelled prostate-specific membrane antigen (PSMA PET-CT) is a novel imaging modality that may have advantages over the aforementioned imaging techniques. It allows for rapid and contemporaneous assessment of both loco-regional and distant metastatic disease. There is also emerging evidence to suggest that PSMA PET-CT is highly sensitive and specific in detecting recurrent disease. The objective of this study is to evaluate the effectiveness of PSMA PET-CT as a single modality in primary prostate cancer staging. Introduction and Objectives: One of the advantages of laparoscopic nephrectomy is that it allows the surgeon to make a smaller incision and thus reduce postoperative morbidity. The requirement to make a larger incision to facilitate organ retrieval may negate this benefit. A challenging clinical dilemma involves deciding whether to make a larger incision or to apply more force to the specimen retrieval system. More force may result in rupture of the bag with subsequent spillage of the contents, potential seeding of the tumour or wound site infection. Knowledge of the force required to cause rupture would potentially aid this decision-making process. Methods: We designed an in-vitro model to assess the force required to rupture standard 15-mm Endocatch bags containing simulated kidneys through an incision in a simulated abdominal wall. We compared these to a control model and related the forces to real life. We also ascertained which part of the specimen bag ruptured to assess if this would lead to sound site seeding and spillage. Results: The mean force was 39.0 AE 6.9 KgF and the mean displacement was 678.4 AE 72.7 mm. Ignoring the sample that slipped (sample 4) that improves to 36.4 AE 3.1 KgF and 650.8 AE 29.6 mm. Of note is the increased stiffness of the "bag only" model which suggests that the skin provides some security when pulling. They all failed either on the lowermost seamline or in the case of one, immediately beside it, none at the incision site despite it being prohibitively small. We related this to real life by gauging how much force a surgeon would ordinarily exert before resorting to extension of the incision. Conclusions: An understanding of the force required to rupture a standard organ retrieval system may help facilitate smaller incisions and reduced postoperative morbidity and complications in the setting of laparoscopic radical nephrectomy.
Introducing entrustable professional activities (EPA) into trainee evaluation: whole professional activity assessment may be more complete than current tools Introduction and Objectives: A qualitative interview based perspectival study of opinion leaders in urological education outlined the need for more complete assessment mechanisms within the training program. Current tools include a quarterly summative assessment report, log book with mini-clinical examination (Mini-CEX) and direct observation of procedural skill (DOPS) evaluation. All tools are valid however there is no current 'whole professional activity' sign off. This is where a trainee is designated as competent to perform a professional activity unsupervised. EPAs fit well into fulfilling this need.
Methods: A literature review was undertaken to explore the role of EPAs in the assessment of urology trainees. This was then used to consider how current Mini-CEX and DOPS assessments could be adapted into EPA templates. Results: The assessments of EPAs are in keeping with the current assessment tools including logbooks, Mini-CEX and DOPS. This formalises and helps document performance of clinical parameters currently not measured directly but nevertheless evaluated in a less formal manner. In addition, assessing the components of the EPA will assist the supervisor and trainee to appreciate the trainee's learning needs to achieve competence. Mini-CEX and DOPS offer an evaluation of specific 'bite size' clinical activity, for example, parts of vasectomy clinical activity could be evaluated into a Mini-CEX and DOPS. The EPA equivalent incorporates the initial consultation and consent process (Mini-CEX) but in addition, adds the organizational aspects of booking the procedure and then undertaking the procedure (DOPS) but includes after-care and follow-up, in this case; wound management, timely semen analysis and final discharge. This allows a teaching unit to 'sign off' all aspects of the professional activity. An advanced EPA could be the assessment, consent, with organization and procedural management and after-care for bladder outlet surgery due to significant lower urinary tract symptoms. A more basic example is a trainee-led clinical ward round. These types of EPAs can be used to encompass the required clinical competencies.
The conditions of EPAs:
• Is part of essential professional work in a given context;
• Must require adequate knowledge, skill and attitude;
• Must lead to recognized output of professional labour;
• Should be confined to qualified personnel;
• Should be independently executable;
• Should be executable within a time frame;
• Should be observable and measurable in its process and outcome (graded);
• Should reflect one or more compe- Introduction and Objectives: Surgical audit is a comparison against recognised standards of current surgical practice in order to improve the quality of care to patients. Previously our audits have required data entry for each patient procedure that are not only time consuming but result in duplication of information already captured in the electronic medical record. Using the Genie software program our aim was to reduce the duplication of data entry fields required for an audit of patients undergoing onabotulinumtoxinA injections into the bladder. Methods: Working with our local Genie software agent we were able to enter required complications and follow up details into the operation record. The operation record already had existing patient details from when a procedural booking was scheduled, therefore these did not need to be re-entered into another audit database. A report was created to export to Excel with the desired data fields for the audit. The recall system was used for patient follow up.
Results: Data fields already entered when scheduling a procedure that did not need to be re-entered were; name, date of birth, age, gender, procedure, patient ID, procedure date, anaesthetic type, and surgeon. Data fields entered by the surgeon at the time of surgery were the onabotulinumtoxinA dose and the recall date.
Data entered by nurse at review were the treatment number and any complications.
Using the recall system for patients not rescheduling repeat injections, the reason for discontinuation was entered.
The list of complications and follow up details were customised to a drop down list to select from and more options can easily be added at any stage.
By building a report, the require data fields can be extracted into an Excel spreadsheet quickly and simply at any time by clinical or support staff.
Conclusions: Surgeons are required to participate in Surgical Audit as a Category 1 CPD activity annually for RACS. The requirements for surgical audit are likely to increase over time with additional requirements for accreditation and recertification. It is necessary for this process to be as accurate and efficient as possible, to minimise the time it takes for surgeons to comply and optimise the quality of the data and thus the results. Using information already collected in the electronic medical record avoids duplication of data entry. This system allows ongoing audit data collection with minimal effort and data can easily be extracted to Excel at any time. This system could be applied to other procedures in any practice using Genie software.
Adapting adult learning theory into surgical education and clinical practice P. RASHID Urology Centre, Port Macquarie, Australia Introduction and Objectives: Surgical education continues to evolve from the master-apprentice model. Newer methods of process need to be used to manage the dual challenges of educating while providing safe surgical care. This requires integrating adult learning concepts into delivery of practical training and education in busy clinical environments. Methods: A literature review aimed at outlining and integrating adult learning and surgical education theory was undertaken. Additionally, this information was used to relate the practical delivery of surgical training and education in day-to-day surgical practice. Concepts were sourced from education texts and coursework materials. Additional material was found using a PubMed search of the words: 'surgical education theory' and 'adult learning theory medical'. This yielded 1351 abstracts, of which 43 relevant articles were used with additional cross-referencing of further sources. Key papers were used to formulate structure and additional cross-referenced papers were included where appropriate. Results: Stepwise learning can be improved to help address global proficiency issues coupled with changing working conditions, reduced hours and limited early clinical experience. Current concepts within adult learning have a lot to offer when considering how to better deliver surgical education. Better integration of adult learning theory can be fruitful. Examples of working models are offered to help supervisors manage their training obligations. Conclusions: Individual teaching surgical units need to rethink their paradigms and consider how each individual can contribute to the education experience. Up skilling courses for trainers can do much to improve the delivery of surgical education. Understanding adult learning concepts and integrating these into day-to-day teaching can be valuable.
Learning about the ANZ SET urology program from a perspectival qualitative study of the views of opinion leaders P. RASHID Urology Centre, Port Macquarie, Australia Introduction and Objectives: In order to assess the RACS/USANZ Urology training program, a prospective qualitative review was undertaken evaluating the origins of the program but more importantly, the challenges facing the delivery of high quality urological training now and into the future. The specific aspects of enquiry related to what some of the perceived issues were and what could be done to resolve areas of concern. Methods: Ethics approved semi-structured template based qualitative interview techniques were employed to evaluate key aspects of the current urology training program. 20 opinion leaders were interviewed for transcription and analysis. Those interviewed were urologists and management staff involved in the SET Program. Grounded theory was used with thematic analysis to assess the data. Initial impression of the data was used to identify critical codes and themes. These were then developed and abstracted to bring together global concepts. Results: 34 themes were extracted. The evolution of urology training was documented. The pathway into training has changed several times over the years. Some of the challenges affecting the BST/AST model were explored and the reasons for the creation of SET outlined. The rush to create SET, under jurisdictional pressure, disenfranchised many surgeons and there is still frustration and anger directed at the RACS. Selection processes became nationalized with SET and that too created problems which are still being resolved. SET has been modified for the 2016 intake (nSET). Flexible training continues to be an elusive goal. Women have enriched the specialty and continue to encourage change in a positive direction. The changes in the program have opinion leaders concerned that the "pendulum has swung too far." Despite interest, simulation technology remains in its infancy with only practical use of basic models. Surgical teachers will only truly develop if appropriate resources are allocated. Additionally, the structure of the Board of Urology needs to evolve as there is little time or resource allocation for innovative development. Management of under-performance of trainees is challenging and continues to occupy a significant and dis-proportionate allocation of resources. Conclusions: The ANZ SET Urology Program began as many of the other surgical specialties from humble beginnings. It is now a robust program but there remain areas needing improvement. The creation of SET changed the program is a very tangible way. That improved the program but created new challenges. The workload for supervisors and office-bearers has been increasing ever since and the pro-bono model may need to be reconsidered. Management of under-performing trainees takes time and resources away from innovative educational development.Abbreviations used:
ANZ Introduction and Objectives: The MBS Review Taskforce is undertaking an independent clinician-led review of the Medicare Benefits Schedule (MBS). This is the first comprehensive review in 30 years of the 5,700 items covered in the MBS. The priority with this Review is to ensure that the items on the MBS are aligned with contemporary clinical evidence and practice and improve health outcomes for all Australians. The Taskforce will also seek to identify any services that may be unnecessary, outdated or potentially unsafe.
The Taskforce is committed to providing recommendations to Government that will allow the MBS to deliver on each of these key goals:
• Affordable and universal access • Best practice health services • Value for the individual patient • Value for the health system.
The clinical review of MBS items, ranging from consultations, procedures and diagnostics is carried out by discipline specific clinical committees and working groups. At the same time the MBS Principles and Rules Committee appointed by the Taskforce are reviewing the enforceable rules and regulations underpinning the MBS so they are up-to-date and support contemporary clinical practice. To date, more than 300 clinicians and there are nearly 60 committees and working groups that have been or are in the process of being established, reviewing the items, line-by-line. Methods: The Taskforce has endorsed a methodology whereby the necessary clinical review of MBS items is undertaken by Clinical Committees and Working Groups. The Taskforce has asked the Clinical Committees to undertake the following tasks:
1 Consider whether there are MBS items that are obsolete and should be removed from the MBS. 2 Consider identified priority reviews of selected MBS services. 3 Develop a program of work to consider the balance of MBS services within its remit and items assigned to the Committee. 4 Advise the Taskforce on relevant general MBS issues identified by the Committee in the course of its deliberations.
The Urology Clinical Committee will be established in 2017 and will be looking at a total of 247 MBS items in the course of their review. Results: Committees release reports with draft recommendations and invite stakeholder feedback. The recommendations do not represent the final position on items and remain subject to consideration of stakeholder feedback and the Taskforce. The Taskforce will then deliver finalised recommendations to government throughout the MBS Review process and deliver a final report to government at the end of the MBS Review.
To ensure the MBS remains up-to-date the Taskforce will also develop an ongoing system of review after this current review is completed. The resurgence of the renal biopsy:
Introduction and Objectives: The rise in detection rates of small renal masses through advancements in imaging technology has led to a rise in the number of renal biopsies being performed in recent years. However, minimal guidelines exist regarding who should undergo biopsy. Patient factors and tumor characteristics provide a starting point for clinical decision making but the lack of a well defined management pathway may lead to dissenting views in multidisciplinary meetings. We review the current literature to identify factors influencing the decision to biopsy and if this is appropriate in patients planned to enter into surveillance programs. We offer a new management algorithm based on the growing body of evidence to guide clinicians in their decision-making. Methods: A formal PRISMA literature review was undertaken using EMBASE, PubMed and Web of Science. MeSH terms were used including: Tumor volume, renal tumor, Kidney biopsy, each combined with a keyword search of Small renal mass. Abstracts and non-English papers were excluded from our analysis. These were then analyzed to create our management algorithm. Results: The literature suggests that biopsy of small renal masses should only be considered in situations where biopsy may alter management. Well established indications for renal biopsy should be considered as absolute Indications and include known extra-renal primary malignancy, suspected lymphoma, abscess, prior to ablative therapy and in patients with prior history of renal cell carcinoma. Other indications are determined by tumour and patient factors and are less clear. We suggest mediated discussion with the patient about benefits and pitfalls of biopsy in these settings. Relative Indications include the absence of absolute indication and tumour size ≥3 cm (due to the increased chance of being higher grade (Fuhrman III-IV)) and females, especially those younger than 68. Patients going into treatment with high RENAL nephrometry score and patients being considered for active surveillance of lesions may benefit by avoiding unnecessary surgery. Comorbidities that predispose to chronic kidney disease or pre-existing renal disease may warrant biopsy to avoid further compromise of renal function post-operatively. Poor indications for renal biopsy include patients in which biopsy is unlikely to change overall management (i.e. high chance for total or partial nephrectomy regardless of result) and those patients with comorbidities that would preclude operative management if biopsy were to be positive. Patients ≥75 should not require biopsy and presence of comorbidities such as those in the Cardiovascular Index that reduce overall survival may also be a contraindication to biopsy. Conclusions: A paradoxical increase in the detection of small renal masses and renal cell carcinoma but steady mortality rate suggests over treatment of small renal masses, particularly in an older population with increasing comorbidities. In evaluating which patients may benefit from a renal biopsy, our recommendations guide clinicians towards best management with a postulated reduction in unnecessary renal biopsies. Appropriate biopsy also affords patients the option of active surveillance and allows for more appropriate interventions to take place where biopsy results support extirpative surgery, reducing healthcare burden and patient morbidity.
Initial experience with the ATOMS sling for the treatment of male urinary incontinence A. WESTENBERG Bay Urology, Tauranga, New Zealand Introduction and Objectives: The ATOMS sling is an anchored adjustable suburethral cushion utilized for the treatment of male urinary incontinence. We report on our initial experience with this novel device. Methods: This is a retrospective observational trial with a mean follow-up of 12.5 months (2-17 months). Data collected included pre-and postoperative validated urinary incontinence instruments (IIQ7, UDI 6), quality of life scores, pad usage and post-operative urinary flow rates. Results: Between May 2015 and August 2016 37 patients underwent placement of an ATOMS sling. 32 patients had urinary incontinence as a result of radical prostatectomy. 9 of these had also undergone salvage radiotherapy (24% of the group). In 29 patients the ATOMS sling was performed as a primary procedure, the remaining 8 had undergone previous antiincontinence surgery (3 AUS, 5 AdVance sling). All but 2 patients had a valsalva leak point pressure of less than 100 cm water. An average of 2.6 postoperative adjustments were required (0-7) with an average total device volume of 14 ml. Postoperatively 42% of patients were pad free and 78% used 0-1 pads per day. 3 patients experienced no improvement. Urinary distress improved postoperatively as in the table below. There were 3 wound infections, 1 successfully treated with antibiotics, one with explanation of the scrotal port and one patient with a recent infection is probably going to need the device removed. 4 patients developed significant postoperative neuropraxia requiring greater than 2 weeks of analgesia but all resolved with time. The average postoperative flow rate was 18 ml/s. Conclusions: Although follow-up is relatively short, the ATOMS sling is a promising technique with a reasonable success rate in an often difficult patient group including those who had undergone previous irradiation. Patient satisfaction is high, adjustments are straightforward in an outpatient setting and morbidity is acceptable. It presents a useful salvage option in patients who have previously failed other continence treatments.
Mean and range of tested parameters pre and post-operatively. Results: A total of 50 patients were identified since January 2011. The median age was 49 years (range 19-77). The strictures were primarily idiopathic in nature (n = 27; 54%), with iatrogenic strictures from traumatic catheterization or post instrumentation second most common (n = 17; 34%). Congenital strictures were least common (n = 6, 12%). Crural separation was seen in nearly half the patients (n = 23, 46% Timing of orchidopexy for undescended testis: a quality of care study Introduction and Objectives: Strong evidence suggests that in order to prevent irreversible testicular damage surgical correction (orchiopexy) for undescended testis (UDT) should be performed before the age of one year. Recently, a large database study in USA demonstrated that despite this strong guideline recommendation, only 16% of children undergoing orchidopexy in USA fall under this recommendation. The Objective of the current study is to evaluate whether a delay in orchidopexy also exists in our medical system, and if so, to explore the pattern of referral for orchidopexy as a possible contributing factors for such delays.
Methods:
Step I -A retrospective chart review of all children who underwent orchidopexy for UDT between 2003 and 2013 in our institution. We collected data regarding the age at surgery, background diseases, and type of health insurance.
Step II -we surveyed pediatricians from around the country and asked for their pattern of UDT patients' referral to a pediatric urologist or a pediatric surgeon for surgical correction.
Results:
Step I -A total of 813 children underwent orchidopexy in our institute during the study period. The median age at surgery was 1.49 years (Range 0.5-13). Only 11% of the children underwent surgery before the age of one year, 53% between the ages of one to two years. We found that these findings were consistent throughout the years we examined, with no difference between the four different health insurance plans children belonged to. 79 (9.7%) of the children had major underline diseases. In this group of patients the median age at surgery was 2 years.
Step II -Sixty-three pediatricians who participated in the survey reported that they referred children to surgery (a urologist or a pediatric surgeon) at a median age of one year (range: 0.5-3 years).
Conclusions: Half of the children in our institute underwent orchidopexy for UDT were 18 months or younger at the time of surgery, and most of them were operated on before they reached the age of 24 month. These findings are superior to those reported in USA, yet are still not optimal. There is a need to improve awareness for early specialist consultation in order to facilitate earlier surgery and better care. Introduction and Objectives: The current policy at a tertiary hospital in Perth dictates that patients under the age of 14 presenting with suspected testicular torsion be transferred to a paediatric hospital. This policy is informally referred to as the 'Adrian Mole Rule,' in reference to the fictional protagonist in book, The Secret Diary of Adrian Mole, Aged 13 ¾. The following study was performed as a clinical audit to determine compliance with this policy and review patient outcomes to determine whether this policy ensures safe and timely provision of care. Methods: All adult and paediatric patients presenting to a tertiary hospital in Perth with acute testicular or scrotal pain from 1 February 2015 to 1 August 2016 were included. Results: 81 patients presented to the tertiary hospital with acute testicular or scrotal pain. 22 patients presented with >24 h of symptoms; the average duration of symptoms for remaining patients was 3 h and 53 min. The average time from emergency department (ED) presentation to first doctor review was 16 min and 37 s.
The average age of all patients was 18. 35 patients (43%) were under the age of 14 with an average age of 10 and an average weight of 42.8 kg. The heaviest child under 14 was 95 kg. 33 of the 35 paediatric patients (94%) were transferred to the paediatric hospital as per policy. Presentation at the tertiary ED to transfer and presentation at the paediatric ED took an average of 38 min and 15 s. 22 adult patients and two patients under 14 underwent an emergency scrotal exploration at the tertiary hospital. The average time from ED presentation to theatre at the tertiary hospital was 3 h and 12 min. The most prevalent diagnosis amongst patients treated at the tertiary hospital was likely intermittent torsion (12) and torsion (12). 10 cases of testicular torsion were successfully detorted and re-perfused with two orchiectomies performed in adult patients.
21 patients underwent an emergency scrotal exploration at the paediatric hospital. Presentation at the paediatric ED to theatre took an average of 3 h and 46 min. The most prevalent diagnosis amongst paediatric patients was torted hydatid appendages (15) followed by likely intermittent torsion (5). There was only one torted testis which was successfully detorted and re-perfused. Conclusions: There was a 94% compliance rate with the age-related policy. Patient review and transfer occurred in a timely manner with time barriers to care amongst both adult and paediatric patients being delay in presentation and delay in getting patients to theatre.
The Adrian Mole Rule may be considered safe as no child transferred to the paediatric hospital had a deleterious outcome with only one diagnosis of testicular torsion and no orchiectomies necessary for transferred patients.
Impact of renal graft volume in the renal function of patients who undergo kidney transplantation
Introduction and Objectives: Kidney Transplantation (KT) is, nowadays, the gold standard treatment for patients with end stage Chronic Kidney Disease (CKD). Many factors contribute for the long term success of a KT, improvement of immunosuppression treatments and the donor clinical conditions certainly appear to be important. Some recent image studies suggest that bigger volume kidneys, seen in CT or MRI offer advantages in the final eGFR of patients who underwent KT. However, this subject is still controversial. The aim of this study is to evaluate if there is strong correlation between the size/volume of donated kidneys and final eGFR and Creatinine. Methods: We performed a Prospective Study with patients who underwent KT at Hospital das Clinicas from Botucatu Medical School -Sao Paulo State University from January 2011 to January 2015. In that period, 196 kidneys from both deceased and also live donors had their size/volume evaluated by three different measures (length, width and thickness) accurately measured during the back table surgery after Euro Collins perfusion. Each kidney volume was estimated using the ellipsoid formula -4/3.pi.a.b.c and the final result corrected by the corporeal surface (KVCS) of the receptor patient. These results were matched with eGFR (Cockroft-Gault Formula) using the Creatinine levels at the sixth month after the KT. Other information as gender, age, BMI and the CKD origin were also analysed. Results: From a total of 197 patients analysed, 9 were excluded due to graft loss, 7 due to death, 2 performed their KT in another hospital, 11 were without kidney volume at their case notes e 4 did not complete 6 months after surgery to check creatinine in time for statistical analysis, having by the end only 164 patients. We found strong and significant linear correlation between the 6 months eGFR and the KVCS, with p = 0.001 and pearson p = 0.252. Also, there was correlation with 6 months creatinine with p = 0.005 and pearson p = 0.217. We found good correlation in both live and deceased donors. Conclusions: The positive correlation between KVCS and eGFR associated with the inverse relation KVCS and creatinine six months after KT leads us to believe that the kidney volume plays an important role which positively interfere in the renal function of patients who undergo Kidney Transplantation. This also could help in better selection of live and even deceased donors aiming better clinical results after KT.
Reconstructive Urology/Transplant
Dynamic compression of the urethra: functional ultrasound imaging of the male transobturator sling with medium term follow-up Introduction and Objectives: There is increasing use of transobturator slings in the treatment of post-prostatectomy stress urinary incontinence (PPI) but the mechanism of action of these slings remain unclear. Our previous ultrasound studies have demonstrated the phenomenon of 'dynamic compression' of the urethra during Valsalva and cough in patients with AdVance slings. The aim of this study was to evaluate any changes in sling position and the concept of dynamic versus passive compression of the urethra as potential mechanisms of action of the male sling in a cohort of patients followed over 4 years. Methods: Transperineal ultrasound was performed on 25 patients who underwent AdVance transobturator sling for PPI, preoperatively and postoperatively at 1, 12, 24 and 48 months. 2D Ultrasound examinations were conducted using a SonoSite MTurbo ultrasound machine and 2D/3D imaging using Philips IU22/EPIQ ultrasound machines and matrix transducer.
Patients were imaged at bladder volumes of over 150mls at rest and on Valsalva.
Results: All 25 Advance slings were well visualized on transperineal ultrasound in the mid-sagittal plane. The AdVance slings were located at or above the inferior border of the pubic symphysis in continent patients but slings were located more distally in the perineum in 3 patients with early sling failure, 2 of these had paradoxical distraction/opening of the urethra on Valsalva. Dynamic compression of the urethra by the AdVance sling was demonstrated with Valsalva and coughing in patients with successful slings at 4 weeks and this was unchanged on serial imaging over 4 years. All 4 patients who had previous radiotherapy had worsening incontinence over the followup period despite dynamic compression demonstrated on imaging.
Conclusions:
Longitudinal functional ultrasound studies demonstrated that the AdVance sling remains in a stable position over time in all patients who had a successful initial outcome and satisfactory sling position. Dynamic compression of the urethra by transobturator sling was consistently observed on serial imaging suggesting that this may be a mechanism of action of the male transobturator sling in addition to passive compression. Introduction and Objectives: Urethral stricture disease management can be challenging. Few guidelines exist in this area and there is little data in the literature for the distribution of patients and presentation types to urologists, especially at a local level. In this study, we aimed to characterise the modes of presentation, types of demographic, and the management of patients with urethral stricture disease presenting for management through our health service over a 10-year period. Methods: Patients with admissions to University Hospital Geelong from 1/1/ 2006 to 31/12/2015 with a diagnosis of urethral stricture disease were identified through medical coding. Chart reviews were completed with documentation of presentations, interventions, follow up and voiding status. We excluded patients who were female or paediatric, had no intervention performed at our health service or, after investigation, had no confirmed urethral stricture. We describe a novel approach using preoperative hook-wire localisation of PSMA-PET positive nodal tissue to improve localisation of target nodes. Methods: A patient who had previously undergone robot-assisted laparoscopic prostatectomy and radiation therapy to the prostate bed was investigated for BCR with PSMA-PET/CT. This displayed 2 PSMA-avid nodes in the left pelvis only and the patient was planned to undergo salvage lymph node dissection. Given the difficult position of one of the target nodes (postero-lateral pelvic wall in close proximity to rectum) pre-operative CT and PSMA-PET/CT images were used to place a hook-wire into the affected target nodal tissue. Results: The patient underwent a successful lymph node dissection. Intra-operative localization of the affected nodal tissue was reported by the operator to be much improved with the specimen and hook wire easily able to be palpated and removed. Histopathology revealed both sites found to be avid on PSMA scanning to yield metastatic prostate cancer. The patient is currently being and will continue to be followed up with serial prostate specific antigen measurements. Conclusions: The use of PSMA-PET/CT has increased exponentially since its introduction. The clinical utility of the specific localization of target nodes has been shown in relation to diagnosis but has so far been limited to descriptive information for surgeons to use intra-operatively. The use of physical localization of target tissues with hook-wires allows us to further improve our accuracy in node dissection and increase the yield of resected tissues. This novel approach is likely to be refined with ongoing use but had significant potential to improve surgical outcomes for patients, especially those with difficult access to nodal tissue. Introduction and Objectives: Historically, radical prostatectomy (RP) was reserved for men with cancers clinically confined to the prostate. With improved surgical technique and understanding of the disease, RP is increasingly offered for locally advanced prostate cancer. RP in T3 prostate cancer may be associated with incomplete local tumour control, and functional outcomes may be worse because of the need for wider resection margins. We examined the oncological and functional outcomes in of patients undergoing RP in T2 and T3 prostate cancer. Methods: A retrospective review was conducted including all patients listed in the SA-PCCOC database who underwent RP with stage pT2a-c or pT3a-b prostate cancer (any PSA, and any biopsy Gleason score). Demographics, PSA values, imaging characteristics, pathological details, intraoperative blood loss and length of stay were recorded. Oncological outcome was assessed by final histology report, margin status, and presence of and time to biochemical recurrence. Functional outcomes were assessed using the EPIC 26 questionnaire (urinary incontinence and erectile dysfunction domains). Results: 1254 patients underwent RP for pT2, and 1297 patients for pT3 prostate cancer. In the patients with pT2 prostate cancer PSA values were <4 in 9.4%, 4-10 in 45.8%, 10-20 in 10.7% and > 20 in 1.4%. In the patients with pT3 prostate cancer PSA values were <4 in 5.6%, 4-10 in 37.2%, 10-20 in 14.3% and > 20 in 3.6%. The Gleason scores in patients with pT2 prostate cancer were 3 + 3 in 51.9%, 3 + 4 in 30.3%, 4 + 3 in 9.4%, 4 + 4 in 5.2%, 5 + 4 in 3.2% patients. The Gleason scores in patients with pT3 prostate cancer were 3 + 3 in 25.8%, 3 + 4 in 35.1%, 4 + 3 in 21.7%, 4 + 4 in 16.1%, 5 + 4 in 1.3% patients. No significant difference was observed in blood loss and length of stay between the groups (p = 0.85 and 0.83, respectively). Nerve sparing surgery was more frequently performed in patients with pT2 disease compared with pT3 (85.7% vs. 75.8%, p < 0.001). Despite this, the erectile dysfunction and urinary continence rates were comparable in the two groups. pT3 patients were at higher risk of biochemical recurrence (BCR) than pT2 patients (HR 1.96, 95% CI 1.6-2.5, p < 0.001). Factors influencing biochemical recurrence were PSA >20 at presentation (HR 1.9, 95% CI 1.7-5.3, p < 0.001), positive margin (HR 2.9, 95% CI 2.4-3.5, p < 0.001), high Gleason scores-Gleason 4 + 3 (HR 4.2, 95% CI 3.0-5.9, p < 0.001) and Gleason >7 (HR 5.2, 95% CI 3.6-7.7, p < 0.001). Conclusion: This study suggests that treating T3 prostate cancer with surgery results in acceptable outcomes. Although T3 patients have an increased risk of BCR compared to T2 patients, the functional outcomes are comparable. This is despite a difference in the rate of nerve-sparing surgery in the groups.
Outcomes of redo-urethroplasty in
Is multiparametric magnetic resonance imaging (MPMRI) in a public tertiary hospital feasible and accurate for prostate cancer detection? A retrospective cohort study Introduction and Objectives: Improvements in multiparametric magnetic resonance imaging (mpMRI) of the prostate and use of the Prostate Imaging Reporting and Data System (PIRADS) has standardised mpMRI reporting and improved patient selection for biopsy. Screening of patients referred to a public tertiary urology unit using mpMRI was recently implemented and we sought evaluate the feasibility and accuracy of mpMRI-based prostate cancer detection in this setting. Methods: All patients referred to the Royal Brisbane and Women's Hospital (RBWH) between 1st July 2014 and 1st July 2016 considered for prostate biopsy were referred for mpMRI. Those who progressed to transperineal biopsy were included in the study. The mpMRI results and other clinical details, including serum prostate specific antigen (PSA), prostate volume (per MRI estimate), PSA density, mpMRI PIRADS score, number of needle biopsies and biopsy histology was gathered retrospectively. Results: 124 patients were included in this study and underwent pre-biopsy prostate mpMRI, of which 43 (34.6%), 43 (34.6%), 24 (19.3%) and 14 (11.3%) patients were in PIRADS groups 5, 4, 3 and 2 respectively. Higher PIRADS scores correlated with a median higher PSA (9.9, 6.4, 8.8, 4 .7 ng/ml) and median PSA density (0.24, 0.17, 0.10, 0.09 ng/ml/cm 3 ) for PIRADS 5, 4, 3, 2 and 1 respectively. 124 patients underwent transperineal prostate biopsy (TPPB) using cognitive fusion and template approaches. Higher PIRADS scores lead to increased prostate cancer detection, with 96%, 81%, 50% and 36% for PIRADS 5, 4, 3, 2 and 1 respectively. The aim of this study is to compare the perioperative and continence outcomes for men undergoing an open radical prostatectomy performed by either a trainee or a consultant in a teaching hospital. Methods: We prospectively collected data from radical prostatectomies performed by four consultants and all SET 3-6 trainee urology registrars between January 2010 and February 2015.
The outcome measures presented in this paper are length of operation, blood loss and pad usage at one year. Results were analysed using the unpaired student's-t test. Results: 428 men underwent radical prostatectomy at Christchurch Public Hospital during this time. Age ranged from 41-76 year with a median of 65 years.
351 (82%) completed the pad usage surveys at one year.
Overall 73% were performed completely by the consultants and the trainee performed 27%.
Median operating time was 105 min (range 42-184 mins) Median blood loss was 500mls (range 100-3000mls) Table one shows comparison of the operating times and blood loss between consultants and trainees performing the operations.
14 men (4%) used 2 pads a day, only two had had their surgery performed by the trainees. 12 men (3.4%) used 3 or more pads a day at one year. These patients were evenly split between the consultant and the trainees. (Table 2) The overall continence status of the two groups showed no significant difference (p = 0.6298). Conclusions: Trainees take longer to perform an open radical prostatectomy than their consultants, but that surgery does not result in an increased blood loss or worse continence outcomes.
Reporting quality indicators to clinicians and hospitals: the prostate cancer outcome registryAustralia and New Zealand S. EVANS Monash University, Melbourne, Australia Introduction and Objectives: In 2009, a prostate cancer registry was established in Victoria with the aim of understanding patterns of treatment and health outcomes, including patient-reported outcomes, after a diagnosis and regardless of the subsequent treatment men received. The registry has subsequently expanded in coverage, with all jurisdictions in Australia and New Zealand contributing data to the national registry. Each jurisdiction has their own registry and is responsible for distributing quality indicator reports to hospitals and clinicians. Some will be receiving their first reports in 2017, as they accumulate enough data to provide confidence in the results.
The objectives of this paper are to (1) describe the evolution of the indicators; (2) outline the reports which are distributed by the registry; and (3) provide an explanation on how the reports should be interpreted. Methods: The quality indicators were developed initially by a small team of clinicians, but in 2014 a larger project was undertaken to determine the national indicator set, involving clinical leaders contributing to the registry and international advisors. With release of government reports and evolving research promoting optimal care pathways and directing guidelines, quality indicators continue to evolve. Feedback from clinicians and hospital administrators reviewing the reports has resulted in generation of time series graphs as well as traditional funnel plots and tables. Results: The hospital and clinician reports contains (1) statistics outlining the total patient recruitment numbers and each hospital's/clinician's contribution to the overall number; (2) a table providing details of patterns of care by risk group and (3) performance against 15 quality indicators of which seven measure health outcomes (mortality, biochemical recurrence and patient reported quality of life for bowel, sexual and urinary function and bother) and eight measure processes of care (timeliness and appropriateness of care, stage of disease at diagnosis, documentation of cT, and completeness of surgical resection adjusted by stage of disease). The National Comprehensive Cancer Network (NCCN) risk categories are used in the report, which is calculated taking into account the patient's Gleason score, clinical t stage and PSA level closest to the treatment date. As a result of feedback that hospitals and clinicians could not easily interpret and track performance, time series have been included. Time series analyses compare individual hospitals performance against population 75th and 90th percentiles. A study to test the interpretability of reports among clinicians, Board Committee members and members of the clinical governance committee in hospitals is underway. Results will be presented. Conclusions: Presenting feedback as part of normal practice, (not as part of timelimited study) and within a continuous quality improvement model has been demonstrated in the literature to improve patient outcomes. Urologists in Australia and New Zealand are leading this work in the management of prostate cancer.
Introduction and Objectives: Urolithiasis in ectopic pelvic kidneys present a challenge in management. The renal pelvis is malrotated and can be associated with a tortuous or high inserting ureter and PUJ obstruction. Its low position and close proximity to bony structures make conventional percutaneous access difficulty. Traditional methods of treatment with SWL, PCNL, Endoscopic approaches often fail or require adjuvant treatment. Laparoscopic approaches have had success in the literature but can be prolonged and require complex handling skills. Emerging robotic approaches draw from laparoscopic experience and offer a safe effective alternative in select patients. We describe our technique of robot assisted pyelolithotomy (RAP) and review the literature for outcomes, indications and guidelines related specifically to RAP in ectopic pelvic kidneys not related to any other pathology. Methods: We searched Pubmed, Embase, Medline, Cochrane Library using terms related to robotic assisted pyelolithotomy and endoscopic or ESWL treatment for ectopic kidneys. We reviewed current guidelines and similar studies to our case report to identify a role for RAP. In our case a 43 years old male with left ectopic pelvic kidney with two calculi up to 2.1 cm. He underwent RAP after two failed attempts at endoscopic approach. After cystoscopy and 5Fr ureteric catheter placement the patient was placed in Trendelenberg and four 8 mm robotic and 2 assist ports were placed as for robotic prostatectomy. A flexible cystoscopy passed through an assist port allowed us to perform pyeloscopy. After complete stone extraction the pyelotomy was closed with a water tight seal using monofilament suture. Results: Total operating room time was 135 min (console 65 min). Estimated blood loss was 20 ml. All drains were removed by post operative day 2 and he was discharged. The stone clearance was 100% with no complications. Review of the literature revealed a high stone clearance with RAP but a deficiency of quality studies and a lack of definitive guidelines regarding RAP for ectopic kidney (table  below) . Conclusions: RAP is a safe feasible approach to consider early after failed traditional approaches. Small studies show benefit in patients undergoing concomitant procedures or used primarily with partial Results: Five patient samples were available for culture with histologically proven metastatic prostate cancer. Two patient samples were successfully cultured for validation after 4 weeks. PSA ELISA of conditioned media was positive, with a value up to 30 ng/ml. RT-qPCR analysis confirmed expression of prostate specific genes PSA, AR, FKBP5 and TMPRSS. In vitro therapeutic screening was performed on a patient derived sample. Next generation sequencing of generated cultures is ongoing. PDX lines were successfully cultured in vitro for the first time. Transfection has allowed genetic manipulation of these PDX models including GFP labeled and inducible AR knockdown LuCaP and BM18 lines for the first time. In vitro cultures were successfully converted back to in vivo tumors in immunocompromised mice. Conclusions: We have been able to successfully culture patient derived samples as well as generate in vitro PDX models using novel culture technology. This suggests the potential role of using patient derived biopsy samples as part of a precision medicine approach to prostate cancer. Genetic manipulation of PDX tumors for the first time in vitro has the potential to increase the utility of these models allowing novel findings and investigations. This technology could provide a vital stepping stone towards precision medicine in the future, involving the rapid generation of in vitro models from a patient to allow therapeutic screening to guide treatment for an individual patient.
Introduction and Objectives:
There is a clinical need for more accurate imaging modalities to detect micro-metastatic or low volume disease in early biochemical recurrence (BCR) after primary treatment for prostate cancer. Positron emission tomography (PET) using a novel prostate specific membrane antigen (PSMA) ligand has been used to detect localized and metastatic prostate cancer lesions with improved sensitivity and specificity compared with standard imaging. Hybrid PET/ Magnetic resonance imaging (MRI) systems yielding MRI characterization of lesions in addition to PET avidity has recently become available. The clinical role and efficacy of this new imaging modality
is not yet established. In a prospective clinical trial, we aim to evaluate the accuracy and clinical implications of PSMA PET/MRI in men with BCR following therapy of curative intent. Methods: A multi-centre, prospective, one-arm observational study has been ethically approved and recruitment initiated at the Princess Alexandra Hospital (PAH). A total of 30 patients are to be recruited with biochemical recurrence defined as PSA > 0.2 ng/ml no sooner than 3 months post radical prostatectomy or PSA 2.0 ng/ml above nadir 2 years post radiotherapy. Suitable patients will undergo PSMA PET/MRI and concurrent standard of care imaging. Patients with lesions amenable for biopsy will undergo sampling for histological correlation. Ongoing management are determined by the PAH prostate cancer multi-disciplinary meeting.
Results: Since recruitment began in March 2016, 13 eligible patients have been recruited. 10 patients had. PSMA PET MRI for review and analysis. PSMA avid lesions were present in 7 patients (78%) with median PSA of 0.57 ng/ml (0.2-32). A total of 4 lesions were identified for biopsy; two lesions were positive for metastatic prostate cancer, one PSMA avid rib lesion was benign and one patient had benign prostatic tissue on biopsy. 8 patients had no disease on standard of care imaging. The lowest PSA with PSMA PET MRI avid disease was 0.23 ng/ml. Conclusions: Hybrid PSMA PET MRI may be useful in staging men with biochemical recurrence, especially when PSA is low. Our preliminary data demonstrates a high detection rate of recurrence, even at PSA <1.0 ng/ml. This modality has the potential to significantly improve prostate cancer detention and allow early identification and management of recurrent disease. This may have implications for earlier salvage treatment, change patient management and allow better survival outcomes.
68-Gallium labelled PSMA PET as a staging tool for patients with newly diagnosed prostate cancer Introduction and Objectives: 68-Gallium labelled prostate specific membrane antigen binding ligand and positron emission tomography (PSMA PET) is increasingly being used to stage patients with newly diagnosed prostate cancer. The use of PSMA PET may help with early detection of metastatic disease and provide opportunities for targeted treatment. Using a prospectively collected database, we assess the distribution of cancer foci as defined by PET avidity in patients with newly diagnosed prostate cancer. Methods: Prospectively collected database was established between Queensland XRay (QXR) and Princess Alexandra Hospital (PAH), Queensland. Patients had the PSMA PET study performed at one of two QXR sites or at PAH using the same imaging protocol. All patients attending for the PSMA PET were eligible for the study. This is an interim analysis of the first (4) months of data collection of patients presenting for staging with newly diagnosed prostate cancer. Where available, final histology from prostatectomy specimens was correlated with the PSMA uptake within the prostate. Results: Seventy-eight of eighty-five patients demonstrated PSMA PET avid primary lesions within the prostate, with a SUVmax of 10.3 + /-7.6. The median prostate specific antigen (PSA) in this group was 8.6 (ng/ml). Four patients were considered to have equivocal avidity with SUVmax between 1.1 and 1.5. 12/85 patients demonstrated seminal vesicle invasion (SVI) or extracapsular extension (ECE). The median PSA in this group was 13 (ng/ml). Six patients were considered to be equivocal for seminal vesicle invasion or extraprostatic extension. Twenty six patients (30.6%) had evidence of nodal and or bone metastases. Eighteen of the 26 patients had PSMA uptake within lymph nodes, 12 of which were confined to the pelvis alone. Median PSA was 10.5 (ng/ml) and median SUVmax was 3.8 within this group. Twelve patients exhibited PSMA uptake within bone. Three patients had other sites of PSMA uptake: pulmonary, left buttock and transverse colon. In patients with lymph node disease, bony lesions or distant PSMA avid lesions, median PSA was 9.75 (ng/ml) (range 0.36-610). Histological correlation for the primary disease within the prostate was available for 69 patients in this study. Sixty six patients had primary PSMA PET avid lesions in the prostate confirmed with histology. Conclusions: This study challenges the previous belief that patients with a PSA <20 (ng/ml) have a low risk of metastatic prostate cancer. In our study patients with metastatic disease had a PSA value of 9.75 (ng/ml), most of which were lymph node involvement in the pelvis. Furthermore, PSMA PET demonstrated PET avidity within the prostate in patients with prostate cancer. These results support the use of PSMA PET as a diagnostic tool for detecting localized prostate cancer.
Propensity matched comparative analysis of characteristics of positive surgical margin following conventional versus retzius-sparing robot-assisted radical prostatectomy and its significance on oncological outcome Introduction and Objectives: RetziusSparing Robot-Assisted Radical Prostatectomy (RS-RARP) has been demonstrated to show equivalent perioperative outcomes with excellent continence rate to conventional anterior approach. Theoretically this approach might be associated with a higher rate of positive surgical margin (PSM) in the anterior location and be preferable for posteriorly based tumour.
We aimed to compare the characteristics of PSM and its significance on oncological outcome between conventional and RS RARP techniques. To the best of our knowledge, this is the first study to compare these oncological parameters between the two techniques.
Methods: A 1:1 propensity score matching was performed to compare PSM and its significance on oncological outcome between conventional and RS RARP cohorts. Age, BMI, prostate volume, Preoperative PSA, clinical T stage and Gleason score at biopsy were included for propensity matching. Incidence, location and multifocality of PSM as well as biochemical recurrence (BCR) were analysed. Kaplan-Meier curve was used to estimate and compare biochemical recurrence free survival between the groups according to location and multiplicity of PSM. Multivariable regression analyses were performed to identify predictors of BCR. Results: Patients with clinically localised prostate cancer are included in the study. After excluding patients with incomplete data or ones who received neoadjuvant or adjuvant therapy, 1,119 patients who underwent conventional RARP were matched to 428 patients in the RS RARP group. PSA, clinical and pathologic T staging, tumour volume, Gleason score and lymph node positivity were significantly associated with PSM in both groups. PSM rate was 9.8% in the conventional versus 9.3% in the RS RARP for pathological T2 prostate cancer. There was a significantly increased rate of PSM in the posterolateral region (p = 0.035) in the conventional RARP group whereas a significantly increased PSM rate was noted in the anterior region (p = 0.046) in the RS RARP group. On multivariable Cox regression analysis PSM at the bladder neck/base was a strong predictor of BCR in the conventional group. Conclusions: While RS-RARP is shown to be associated with equivalent PSM rate and short term oncological outcome, this propensity matched comparative study confirmed our belief that it has a lower PSM rate over the posterolateral region but a higher rate at the anterior location. Caution should be taken if tumour is located at an anterior location preoperatively with RS-RARP approach, while it might be advantageous to consider this technique for posterolaterally based tumour.
Comparison of systemic inflammatory markers in the prediction of oncological outcome following robot-assisted radical prostatectomy for clinically localised prostate cancer Introduction and Objectives: There are several systemic inflammatory markers available that are associated with oncological outcomes in various cancers. These markers have been proven to be prognostic for metastatic prostate cancer. However, there is a paucity of evidence with conflicting findings with regards to the best inflammatory marker in patients with localised prostate cancer following robot assisted radical prostatectomy (RARP). We retrospectively investigated the association of several markers with oncological outcomes after RARP. Methods: A retrospective review of prospectively collected data was performed in patients who underwent RARP between July 2005 and October 2012. Patients who received neoadjuvant hormonal therapy or adjuvant therapy as well as ones with incomplete data were excluded. Various oncological parameters such as adverse pathological features (APF), biochemical recurrence (BCR), metastasis, and overall mortality were compared using absolute neutrophil count (ANC), absolute lymphocyte count (ALC), neutrophil lymphocyte ratio (NLR), absolute platelet count (APC), platelet lymphocyte ratio (PLR), CReactive Protein (CRP) and modified Glasgow prediction score (mGPS). KaplanMeier curve was used to assess BCR, metastasis free survival (MFS), and overall survival (OS). Multivariable regression model was performed to identify predictors of these oncological endpoints. Results: Of 1319 patients, 1159 patients met the inclusion criteria. The median age and follow up were 65 years and 62 months (Interquartile range 60-70 years and 44-76 months), respectively. According to D'Amico classification, 309, 492, and 358 patients were stratified into low, intermediate and high risk groups, respectively. Neutrophil and CRP levels were significantly higher in the high risks group. On multivariate analysis, increased NLR was a significant predictor of OS (HR 2.154, 95% Confidence Interval -1.102-4.295, p = 0.026). Furthermore, higher ANC and NLR were predictors of developing APF at radical prostatectomy and MFS in the high risk patient group, respectively. There was no systemic inflammatory marker that was associated with BCR. Conclusions: NLR was shown to be a strong systemic inflammatory marker in predicting OS. ANC and NLR were also strongly associated with APF and MFS in the high risk group, respectively. Further studies are needed to verify our findings.
Predictors of continence after retzius-sparing robot-assisted radical prostatectomy Introduction and Objectives: RetziusSparing Robot-Assisted Radical Prostatectomy (RS-RARP) has been shown to potentially improve continence rate in comparison to conventional RARP. There is lack of information about predictors of continence with this technique. Our aim is to identify early and late predictors of continence following RS-RARP. Methods: A retrospective review of prospectively collected data for patients who underwent RS-RARP for clinically localised prostate cancer was analysed. Patients who received neoadjuvant, adjuvant or salvage therapy or had incomplete continence follow up were excluded. Baseline patient characteristics as well as perioperative and pathological outcomes were evaluated. Continence was defined as no pad or a safety liner. Continence was assessed at 3 and 12 months using ICIQ urinary incontinence-Short form. Continuous variables were reported as mean AE SD and as median AEIQR for normally distributed and non-normally distributed variables, respectively. The t test, MannWhitney U test and Pearson's chi-square test were used to compare continuous and categorical variables. Logistic regression analyses were used for univariable and multivariable analyses. Results: There were 309 patients included in the study, of which 18 patients were classified as incontinent at 1 year follow up (94.2%). There was a significant difference in the age (65.9, 71.3 years, p = 0.002), preoperative SHIM (12.2, 6 .8, p = 0.002), IPSS (13.1, 17.6, p = 0.009), and pathological T stage (p = 0.047) between the continent and incontinent groups, respectively. There was no significant association with other measured variables including BMI, ASA, prostate volume, previous transurethral prostate surgery, nerve sparing technique, Gleason grading, and concomitant pelvic lymph node dissection. Age and IPSS were the significant predictors on multivariable analysis at both 3 and 12 months following RS-RARP (Age, p = 0.010, 0.003, and IPSS, p = 0.048, 0.035 at 3 and 12 months, respectively). Conclusions: This is the first study to show predictors of incontinence in RS-RARP. Increasing age (>70 years of age) and preoperative IPSS are shown to be predictors of incontinence in patients undergoing RS-RARP. A more objective study would be beneficial to further identify factors associated with excellent continence rate with RS-RARP.
Introduction and Objectives: Multi-parametric magnetic resonance imaging (mpMRI) of the prostate is now frequently used to plan biopsies, stage known prostate malignancies, and even replace biopsy in active surveillance. In every-day practice it appears that prostate MRI is altering the management of men with rising prostate specific antigen (PSA) or known prostate cancer, with its utilisation often outpacing the literature which confirms its place in the management paradigm. This study aims to assess the clinical utility of prostate MRI by performing a retrospective faux multi-disciplinary team meeting and comparing treatment decisions with and without MRI results to see how the use of MRI changes patient management. Methods: Three hundred eighty-five patients who underwent prostate MRI in a regional centre were available for inclusion. Twenty five patients were carefully selected who underwent MRI prior to active treatment of intermediate or high risk prostate cancer. In this setting MRI was performed for the purpose of treatment planning. Two reports for each patient were prepared containing de-identified data including age, biopsy results, serial PSA, digital rectal examination findings, prostate volume, erectile function and co-morbidities. One report included MRI results, the other did not. The fifty reports were randomised, and ten duplicates were added in to account for intraobserver variability. Each report was presented in a blinded fashion to two urologists and two radiation oncologists. Available treatment options included surgery with and without nerve sparing, radiotherapy with and without neoadjuvant hormone therapy, high or low dose brachytherapy, or re-biopsy prior to definitive decision.
Results: MRI appears to alter planning for radical prostatectomy in regards to nerve sparing when compared with biopsy alone. MRI does not appear to change management if radiotherapy is the most appropriate course of action. Brachytherapy is influenced by MRI due to the assessment of prostate volume. MRI does change management when disease is thought to be under-sampled, and a different index lesion is identified on MRI. Conclusions: MRI can have a significant clinical impact on treatment of prostate cancer and rising PSA. Care needs to be taken given that clinical decisions may change without prospective trials confirming the safety of altering management based on MRI findings. Larger centre studies with faux multi-disciplinary assessments of cases with and without MRI would provide more information on the now routine use of MRI. Introduction and Objectives: Retroperitoneal Lymph Node Dissection (RPLND) is a highly specialised procedure undertaken in few centres. Generally, UroOncology fellowships are completed to develop the requisite skills to perform this complex surgery. Main indications are for chemotherapy-resistant, lymph node positive, germ cell tumours, however, increasingly there has been a role in other cancer diagnosis, including renal cell carcinoma, urothelial cancer and even with other non-urological malignancies.
We reviewed contemporary short and longer term outcomes from three separate Tertiary Centres across Australia and New Zealand. Methods: A prospective database of patients undergoing RPLND is maintained by each hospital. Medical records and the database were then utilised to update short and longer term outcomes of this procedure from February 2006 until September 2016. 7 different urologists performed the procedures, from 3 separate institutions, all of whom had completed fellowships in uro-oncology. Statistical analysis was then undertaken and comparisons were made to outcomes in current literature. Results: 72 patients were included for analysis; 47 were from Australia and 25 from New Zealand. The average age was 33, all were male with the exception of 2 female patients. The median length of stay was 7 days, with a median intensive care involvement of 9 h. Short term complications were acceptable, with only 12.5% patients requiring readmission for an average length of 5.1 days. No patients died as a result of the procedure. The majority of patients underwent RPLND for non seminomatous germ cell tumours (NSGCT) following chemotherapy, 1 of these with ovarian origin (metastatic). 3 patients had primary retroperitoneal germ cell tumours, 2 had a renal cell carcinoma, 1 an angiosarcoma, 1 a sex cord stromal tumour and 1 with rhabdomyosarcoma. The remainder underwent the procedure for a seminomatous germ cell tumour (SGCT). 4 patients had histology findings significantly different to their initial orchiectomy specimens (NSGCT).
The median operative time was 316 min (range 60-878 min). Operative times were comparable between different cancers. The median intra-operative blood loss was 1000 ml (range 0-6000 ml); 24% of patients required transfusion of blood products intra-operatively.3 patients returned to theatre, 1 for resection of a necrotic recto-sigmoid segment, 1 for insertion of shunt post lymphatic leak and 1 for bilateral calf compartment syndrome. 19% of cases were completed with the assistance of a consultant vascular surgeon.
The average number of resected lymph nodes was 23.1 of which an average of 2.5 nodes were positive in resections. 2 patients within the cohort died during subsequent follow up periods both had pulmonary metastatic disease. 15% of patients had an identified recurrence, and of those with recurrence 80% have survived to date. Conclusions: With updated data we suggest that RPLND may be done safely in high volume tertiary institutions when performed by fellowship-trained surgeons. Successful oncological results were achieved, with comparable outcomes between all centres. Outcomes are competitive with international standards. NSGCT remains the most common oncological subtype for RPLND but increasing numbers of other subtypes are evident, including RCC.
Introduction and Objectives: Percutaneous renal mass biopsies have become more prevalent across Australia over the last 15 years. The overall incidence has been lower in Western Australia compared to other states. This study aims to investigate the overall trends in outcomes of renal mass biopsies in two tertiary centres in Perth. Methods: Retrospective analysis of histological renal cell carcinoma subtype, diagnostic accuracy, concordance, complication and treatment outcome pathways following all CT guided renal mass biopsies at Royal Perth and Fremantle hospital from 2011-2015. Results: In total, 126 CT guided renal biopsies were undertaken for suspicious renal masses at Royal Perth and Fremantle hospital from Jan 2011 to Dec 2015. Of these, 70% were small renal masses less than 4 cm and 30% were larger renal masses. Overall, 77% proved to be histologically malignant and 23% benign. The overall diagnostic accuracy was 93% and concordance was approximately 88%. Around 37% of patients who had a renal mass biopsy had surgery (RN or PN) whilst 27% had surveillance and 15% RFA treatment. Nearly 10% of patients had more than one renal biopsy due to an initial non-diagnostic result and 16% had a small haematoma at the time of initial biopsy. Conclusions: Renal mass biopsies in the public hospital setting confer a relatively safe and accurate diagnosis for the management of radiologically suspicious lesions in Western Australia which is consistent with current literature. A significant proportion of biopsies confer benign pathology which has an overall impact on treatment recommendations and biopsies can aid in avoiding unnecessary surgery.
The implementation of a nurse led renal cancer follow up program in tertiary teaching hospital Introduction and Objectives: Follow up of renal cancer can be haphazard, often performed by multiple clinicians of different grade and experience. We have previously reported the development of evidence and consensus based guidelines grouping patients into low, intermediate and high risk categories and their subsequent follow up post nephrectomy. We report a unique model of nurse led renal cancer follow up. Methods: All data was prospectively recorded. Patients were identified from the Uro-oncology MDT where the risk stratification was allocated. A clinical nurse consultant subsequently coordinates follow up according to the previously defined protocol which documents the nature and timing of follow up necessary imaging, blood investigations and guidance as to when medical input is required. In addition to tumour pathology and risk stratification, data including patient demographics, renal function, BP and adherence to follow up were recorded. Introduction and Objectives: With the emergence of multi-resistant serious infections from transrectal ultrasound guided prostate needle biopsies (TRUSPB), there has been debate as to whether this procedure should be abandoned in preference to a transperineal prostate biopsy (TPB). We sought to evaluate the results from a single surgeon's TRUSPB series. Methods: From a prospectively collected database, between June 2009-May 2016, 872 TRUSPB were performed with 840 (96.3%) performed in an office setting with local anaesthetic infiltration of 10 ml 1% xylocaine and 3 days oral ciprofloxacin prophylaxis. All patients were followed up 2-3 weeks following TRUSPB and a retrospective review of consultant letters/ records to confirm the accuracy of the prospectively collected database. From August 2012, patients with recent overseas travel had their TRUSPB deferred by at least 3 months and a rectal swab to confirm absence of quinolone resistant organisms prior to TRUSPB and from January 2015, patients were also given the option of TPB. Results: From a total of 872 TRUSPB performed, the mean number of cores taken were 17.8 (range 5-30) 1.0% (9 patients) were readmitted due to infection/sepsis. From the 9 patients readmitted with infection/sepsis, only 2 patients required HDU admission and both had recent overseas travel prior to the TRUSPB changes (Aug 2012). All seven other patients readmitted with infection/sepsis had negative cultures. Since the introduction of rectal swabs, delaying TRUSPB after overseas travel and the availability of TPB we have had NO multi-resistant urosepsis cases in our last 494 TRUSPB and no HDU/ICU admissions. Only 4 patients (0.5%) were unable to complete a TRUSPB under local anaesthesia with the procedure terminated prematurely due to inability to tolerate the procedure due to discomfort or a vasovagal episode. Conclusions: For appropriately selected and counselled patients, TRUSPB remains an acceptable method of prostate needle biopsy that is simple, well tolerated with low complication and sepsis rates.
Role of metabolic biomarkers using peak volume analysis in magnetic resonance spectroscopy for diagnosis of renal cell carcinoma Results: 18 matched samples, and 9 unmatched samples of human kidney tissue were analyzed from a total of 45 samples. Of these, 16 matched samples were diagnosed histologically as clear cell RCC [ccRCC] . Using univariate analysis, 3 peaks that demonstrated significant differences between ccRCC, non-ccRCC and normal renal tissue were identified: alanine, valine and lysine. When compared to paired normal kidney, MRS demonstrated peak volumes in ccRCC tissue to be significantly lower for alanine, valine and lysine (p = 0.04, p = 0.03, p = 0.03, respectively). When comparing nonccRCC to ccRCC tumours, peak volumes of valine and lysine were significantly lower in ccRCC (p = 0.004 and p = 0.03, respectively), while peak volume analysis of alanine was not different (p = 0.10). Conclusions: The continued discovery of metabolic biomarkers capable of distinguishing RCC subtypes, using MRS, holds valuable diagnostic and prognostic potential for patients with RCC. Significant decreases in peak volumes of valine and lysine in RCC versus matched normal tissue indicate the potential utility of these biomarkers to distinguish ccRCC versus non-ccRCC subtypes. Introduction and Objectives: Despite multiple resections and long-term chemo and immunotherapy, up to 50% of nonmuscle-invasive TCC patients have recurrence or progression into a muscle invasive disease, potentially leading to cystectomy and a less favourable outcome. Possible reasons for that are incomplete resection and reimplantation of cancer cells, which can be prevented by improved resection and adjuvant therapy. Our objective was to develop a drug for detection, fluorescence-guided resection and deeppenetrating adjuvant photodynamic therapy of TCC. We decided to base this agent on an upconversion nanoparticle (UCNP), which can transform deep-penetrating near-infrared light into high-energy visible light, demanded for tumour-visualization and for production of reactive oxygen species in photosensitizers. Coupled to specific antibodies, these UCNPs had a potential to form a targeted nanoconjugate, that can selectively bind to TCC cells and luminesce, making them visible and activating photosensitisers. Methods: In this project we produced silica-coated UCNP of the composition NaYF 4 :Yb,Er amenable for conjugation with biomolecules. A Glypican-1-specific monoclonal antibody MIL-38, produced by Minomic International Ltd. (Sydney, Australia), was chosen for targeted delivery of nanoparticles as it demonstrated affinity towards some TCC cell lines. UCNPs were conjugated with MIL-38 by using a bifunctional fusion protein Linker-Protein G (LPG). Finally, to investigate targeted binding and molecular specificity of these nanoconjugates, we incubated them with Glypican-1 positive and Glypican-1 negative TCC cells. The role of MIL-38 in targeted delivery of nanoconjugates was also validated by incubation of T24 cells with nanoparticles coupled to a different antibody and without an antibody. Results: Targeted upconversion nanoconjugates UCNP-LPG-MIL-38 labelled almost 90% of T24 cells with high expression of Glypican-1 and only 23.2% of C3 cells with low expression of this antigen, demonstrating high molecular selectivity and specificity. Incubation of T24 cells with nanoconjugates linked with a control antibody and without antibody resulted in labelling of 19.8% and 26.2%, respectively, demonstrating the role of MIL-38 in targeted delivery of these nanoconjugates. As a result of the labelling, mean photoluminescence of cells in targeted group was from five to eight times brighter than in control groups. Conclusions: These results highlight the potential of these nanoconjugates for the diagnosis and therapy of TCC, as they can bind to Glypican-1 positive TCC cells and cause their photoluminescence. It was also confirmed that monoclonal antibody MIL-38 can be applied in experimental diagnosis, drug delivery and targeted therapy of TCC, as it mediated targeted binding of upconversion photoluminescent nanoconjugates to Glypican-1 positive TCC cells.
Impact of PSMA PET CT on the preoperative management of prostate cancer: The Monash experience Introduction and Objectives: To assess whether PSMA PET CT changes preoperative management in the Uro-oncology multidisciplinary meeting (MDM) at Monash Health and to determine the concordance between conventional cancer staging (CT and/or bone scan) and PSMA PET CT. Methods: All pre-operative prostate cancer patients discussed at the Monash Health MDM who underwent PSMA PET CT scanning over a 16 month period were included in this retrospective study. Patient demographics, Gleason scores, PSA, staging information and PSMA PET CT results were analyzed using t-test and ranksum test. Correlation between conventional staging modalities was compared against PSMA PET CT using Cohen's Kappa. Results: 29 patients met the inclusion criteria. Median PSA was higher in patients with positive extra-prostatic PSMA PET CT lesions 35.4 (13-76) than negative 13 (1.8-53) p = 0.005. 14 patients had Gleason 7 disease and 15 patients had Gleason ≥8 disease. All patients had PSMA PET CT avid primary cancer.
26% (6/23) of cases with negative conventional staging were found to have extra-prostatic disease on PSMA PET CT. All 6 cases had their management plan changed as a result. 33% (2/6) of cases with positive conventional staging found no PSMA PET CT evidence of extra-prostatic disease, of which one case had their management plan changed.
Imaging non-concordance was greatest in Gleason 7 cancers-40% of conventional staging negative patients had PSMA PET CT positive extra-prostatic avid disease. Conclusions: PSMA PET CT has resulted in a paradigm shift at Monash Health in the treatment of prostate cancer. All patients with staging positive extra-prostatic pre-operative PSMA PET CT are now treated with radiotherapy. PSMA PET CT is a promising new imaging technique in the pre-operative staging of prostate cancer. It is a useful tool in aiding decision making for treatment. Further research is warranted to better assess its efficacy and implementation.
Metformin can reduce cardiovascular risk factors in men treated with androgen deprivation therapy Introduction and Objectives: Androgen deprivation therapy (ADT) is an essential component of treating men with advanced and metastatic prostate cancer. The treatment is associated with cardiovascular risk factors such as obesity, hypercholesterolaemia, and hyperglycaemia. In this single blinded prospective phase I multisite randomized clinical trial, we assess the metabolic benefits of metformin compared to placebo in men starting ADT. Methods: Consecutive men with newly diagnosed metastatic prostate cancer who are not suitable or unwilling to undergo chemotherapy were recruited. Patients underwent physical and metabolic parameter assessment (glucose, lipids, insulin, leptin, adiponectin and ghrelin) and started on Eligard TM 45 mg with 4 weeks of bicalutamide. At 3 months, patients were randomized into ADT + placebo or metformin treatment groups. Patients were followed up 6 weekly for 54 weeks. Results: 45 patients have been recruited into the clinical trial to date. 28 patients were diagnosed with metabolic syndrome and fourteen with diabetes, impaired fasting glucose or impaired glucose tolerance at the time of starting ADT. At a minimum of 3 months follow-up, 37 patients were available for analysis. Patients demonstrated percentage changes in weight by 0.14%, PSA À86.5%, total cholesterol 7.1%, triglyceride 30.6%, high density lipoprotein À2.9%, low density lipoprotein 17.3%, fasting glucose À10.8%, fasting insulin 10% and homeostatic model assessment-insulin resistance score 7%. 28 patients were available for analysis with 3 months following randomization (Visit 5). Changes in BMI, total cholesterol, low density lipoprotein, glucose and insulin by À0.06%, À3.5%, 9.3%, À5% and À4% respectively were observed with metformin treatment compared to placebo. Conclusions: Treatment with metformin as an adjuvant therapy may be an effective strategy to negate the metabolic effects of ADT in men with newly diagnosed metastatic prostate cancer. In men with a previous history of cardiovascular disease, modest reduction in cardiovascular risk factors may be especially important. These findings provide grounds for a larger randomized clinical trial to assess overall survival of men treated with adjuvant metformin in addition to ADT. Intravesical BCG with or without interferon-alpha for treating nonmuscle-invasive bladder cancer: a Cochrane systematic review Introduction and Objectives: Partial nephrectomy (PN) is the reference standard of management for a cT1a renal mass. However, its role in the management of larger tumors (cT1b and cT2) is still under scrutiny. Our aim was to conduct a meta-analysis assessing functional, oncologic, and perioperative outcomes of PN and radical nephrectomy (RN) in the specific case of larger renal tumors (≥cT1b). Methods: A systematic literature review was performed up to December 2015 using multiple search engines to identify eligible comparative studies. A formal meta-analysis was performed for studies comparing PN to RN for both cT1b and cT2 tumors. In addition, a sensitivity analysis including the subgroup of studies comparing PN to RN for cT2 only was conducted. Pooled estimates were calculated using a fixed-effects model if no significant heterogeneity was identified; alternatively, a random-effects model was used when significant heterogeneity was detected. For continuous outcomes, the weighted mean difference (WMD) was used as summary measure. For binary variables, the odds ratio (OR) or risk ratio (RR) was calculated with 95% confidence interval (CI). Results: Overall, 21 case-control studies including 11204 patients (RN 8620; PN 2584) were deemed eligible and included in the analysis. Patients undergoing PN were younger (WMD À2.3 years; p < 0.001) and had smaller masses (WMD À0.65 cm; p < 0.001). Lower estimated blood loss was found for RN (WMD 102.6 ml; p < 0.001). There was a higher likelihood of postoperative complications for PN (RR 1.74, 95% CI 1.34-2.2; p < 0.001). PN was associated with better postoperative renal function, as shown by higher postoperative estimated glomerular filtration rate (eGFR; WMD 12.4 ml/min; p < 0.001), lower likelihood of postoperative onset of chronic kidney disease (RR 0.36; p < 0.001), and lower decline in eGFR (WMD À8.6 ml/min; p < 0.001). The PN group had a lower likelihood of tumor recurrence (OR 0.6; p < 0.001), cancer-specific mortality (OR 0.58; p = 0.001), and all-cause mortality (OR 0.67; p = 0.005). Four studies compared PN (n = 212) to RN (n = 1792) in the specific case of T2 tumors (>7 cm). In this subset of patients, the estimated blood loss was higher for PN (WMD 107.6 ml; p < 0.001), as was the likelihood of complications (RR 2.0; p < 0.001). Both the recurrence rate (RR 0.61; p = 0.004) and cancer-specific mortality (RR 0.65; p = 0.03) were lower for PN. Conclusions: PN is a viable treatment option for larger renal tumors, as it offers acceptable surgical morbidity, equivalent cancer control, and better preservation of renal function, with potential for better long-term survival. For T2 tumors, PN use should be more selective, and specific patient and tumor factors should be considered. Further investigation is warranted to better define the role of PN in this challenging clinical scenario. Introduction and Objectives: To overcome the toxicities associated with MVAC without giving up a potential advantage with respect to efficacy, the accelerated or dose dense MVAC (ddMVAC) regimen was introduced and shown to be associated with improved overall survival and less toxicity compared to standard MVAC in a randomized clinical trial in patients with advanced bladder cancer. Our primary endpoint was to assess the rate of pT0N0 and ≤pT1N0 for patients with BCa treated with ddMVAC chemotherapy followed by radical cystectomy (RC) in this real-word multi-institutional cohort. Methods: We retrospectively reviewed records of patients with urothelial cancer who underwent ddMVAC and RC at seven contributing institutions from 2000-2015. Patients with cT2-4a,M0 BCa were included. Presence of cT3-4 disease, hydronephrosis, lymphovascular invasion and/or existence of sarcomatoid, or micropapillary features on the initial transurethral resection of bladder tumor specimen was defined as high-risk disease. Logistic regression models for prediction of pT0N0 and ≤pT1N0 were generated for the entire cohort as well as for the cN0 subgroup. The multivariable Cox proportional hazards regression model for survival using post RC data was used to assess hazard ratios (HRs) for the variables of interest. Results: A total of 345 patients received ddMVAC chemotherapy during the study period. The observed rates of pT0N0 and ≤pT1N0 were 30.4% and 49.3%, respectively among cN0 patients. On the multivariable regression model, the presence of more than one clinical high-risk element was associated with 70% (OR 0.30 95% CI (0.10-0.86); p = 0.02) reduction in the probability of achieving partial pathological response. Conclusions: A complete response (pT0N0) was observed in one-third of patients after neoadjuvant ddMVAC therapy, and a partial response (≤pT1N0) was observed in nearly half of the cases in this real-world experience with this regimen. To our knowledge, this represents the largest experience outside clinical trial settings.
Keith Kirkland
The effectiveness of Intraoperative Hyocine Butylbromide (Buscopan) in reducing postoperative catheterrelated bladder discomfort in urological patients: a prospective, randomized, placebo-controlled, double-blinded study Introduction & Objectives: Catheterrelated bladder discomfort (CRBD) is a distressing recovery room symptom in urological patients who require intraoperative insertion of an urethral catheter (UC). The prevalence has been reported as 47-90%.The aim was to test the hypothesis that the administration of 20 mg of * Presence of any of cT3-4 disease, hydronephrosis, lymphovascular invasion (LVI) or existence of sarcomatoid or micropapillary features on TURBT specimen. ** The data for 5 patients were not available and the clinical nodal status of 11 patients was unknown (cNx).
intraoperative intravenous Buscopan willIntroduction & Objectives: Positive surgical margin status is a strong predictor of biochemical recurrence, requirement for further treatment and reduced disease specific survival in prostate cancer. We examine whether pre-operative clinical stage, Gleason score and PSA were predictors of positive surgical margin (PSM) status in Australian men undergoing laparoscopic radical prostatectomy (LRP). Each of these factors has previously been reported to be an independent predictor of PSM risk. Method: Prospectively collected data were obtained from nine Australian surgeons who had performed 2943 consecutive LRP cases. Each patient's preoperative clinical stage, Gleason score and PSA were compared to the pathological presence or absence of a PSM. Ethics approval was granted by the Hunter New England Human Research Ethics Committee (14/ 07/16/5.07). Results: A PSM was observed in 442 of 2943 cases (15%). Mean preoperative Gleason score was 7 and 7, mean PSA was 9 and 7 ng/mL and clinical stage (cT) was non organ confined (≥ cT3) in 2% and 1% of those with and without a PSM respectively. A higher preoperative PSA (p < 0.001) and clinical stage ≥ cT3 (p = 0.002) were significant predictors of PSM status. When a cutoff for preoperative PSA was set at >10 ng/mL this did nearly double the individual prospect of a positive surgical margin (OR 1.9, 95% CI 1.5-2.4 p < 0.001), but had a positive predictive value of only 24% and omitted the majority of PSMs. Conclusions: Although clinical stage and PSA, though not Gleason score, were significant predictors of PSM status following LRP, the similarity and interference in measured values between individual patients with and without PSMs would prevent these indicators from being clinically useful in determining preoperative PSM risk on an individual level. This remained the case even when grouping was performed to accentuate underlying differences.
Is one-off intravenous Cefazolin adequate antibiotic prophylaxis for intra-vesical Botox? Introduction & Objectives: It has been suggested that intra-vesical Botox injections should routinely be covered with a short course of oral antibiotics to reduce the incidence of post-procedure UTI. The evidence supporting this practice is limited, and our routine practice has always been to use only a one-off dose of intravenous Cefazolin in patients with a sterile pre-operative urine sample. Our objectives were to audit our incidence of postoperative UTI using this regime, and consider what regime may be suitable going forwards. Method: The records of all patients undergoing intra-vesical Botox treatment at our centre between June 2007 and July 2016 were reviewed retrospectively. Midstream urine specimens were routinely requested one week pre-and post-operatively over this period. The incidence of post-procedure UTI was calculated after excluding patients with pre-operative UTI, receiving additional antibiotics, or in whom insufficient urine results were available. Fisher's exact test was used to analyse differences in the incidence of UTI between different patient groups. An antibiotic sensitivity analysis was conducted of all positive pre-and post-op urine specimens. Results: 50 patients underwent 128 procedures, with an average of 2.6 procedures each (range 1-14). 60% (30/50) of patients had idiopathic overactive bladder and 72% (36/50) were voiding spontaneously. 23% (24/105) of patients had a positive preoperative urine sample and 28% (32/105) received additional oral antibiotics perioperatively. The incidence of post-procedure UTI in patients with sterile preoperative urine and who only received intravenous Cefazolin was 22% (15/68). Whilst the incidence of post-procedure UTI was not significantly different between neuropaths and non-neuropaths (28% vs. 18%), the difference between spontaneous voiders and catheter-dependent patients approached significance (15% vs. 36%, p = 0.06). An antibiotic sensitivity analysis of 60 infected urine samples over this period revealed the following overall sensitivities: Amoxicillin (29%), Cefalexin (60%), Trimethoprim (70%), Nitrofurantoin (72%), Augmentin (72%), Norfloxacin (95%).
Conclusions:
The incidence of post-procedure UTI following administration of intra-vesical Botox using only one-off intravenous Cefazolin prophylaxis was 22%. We have subsequently changed our antibiotic prophylaxis regimen to the administration of two doses of oral Norfloxacin on the day of surgery. An initial re-audit is planned for October 2017, whilst a further re-audit in April 2020 will be powered to detect a significant improvement in the incidence of post-procedure UTIs.
Introduction & Objectives: Non-prostate urological cancers comprise a significant proportion of the general urology workload with bladder and kidney cancer among the top ten cancers diagnosed in Australia. Testicular cancer is the second most commonly diagnosed cancer in ) at five years and 40.2% (95% CI 27.1-29.5) at ten years. Renal pelvis and ureter five and ten year survival estimates are 36.3% (95% CI 33.5-39.3) and 24.6 % (95% CI 22-27.5), respectively. Conclusions: The incidence of bladder and kidney cancer has steadily increased over the study period, with kidney cancer incidence now overtaking bladder cancer. While incidental kidney cancer diagnosis by medical imaging is likely to be a factor, further sub analysis, particularly of histological type is required. Incidence of other non-prostate urological malignancies remains low and stable.
Although this is a preliminary analysis of the SA Cancer Registry, these data are useful in showing general patterns or changes of incidence of urological cancer in South Australia. The elevated incidence of urological cancer noted in our analysis, particularly kidney cancer, also indicates the need for continued promotion of urological cancer research. Further analysis of these data may provide useful guidance in directing future research of non-prostate urological cancers.
